US20170114385A1 - Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices - Google Patents
Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices Download PDFInfo
- Publication number
- US20170114385A1 US20170114385A1 US15/345,359 US201615345359A US2017114385A1 US 20170114385 A1 US20170114385 A1 US 20170114385A1 US 201615345359 A US201615345359 A US 201615345359A US 2017114385 A1 US2017114385 A1 US 2017114385A1
- Authority
- US
- United States
- Prior art keywords
- microfluidic channel
- flow rate
- particles
- expansion region
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502746—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the means for controlling flow resistance, e.g. flow controllers, baffles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/16—Microfluidic devices; Capillary tubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/04—Cell isolation or sorting
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
- B01L2200/0668—Trapping microscopic beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0864—Configuration of multiple channels and/or chambers in a single devices comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0867—Multiple inlets and one sample wells, e.g. mixing, dilution
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/087—Multiple sequential chambers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0487—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/08—Regulating or influencing the flow resistance
- B01L2400/082—Active control of flow resistance, e.g. flow controllers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/08—Regulating or influencing the flow resistance
- B01L2400/084—Passive control of flow resistance
- B01L2400/086—Passive control of flow resistance using baffles or other fixed flow obstructions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
Definitions
- the field of the invention generally relates to microfluidic devices and methods for the isolation and sorting of cells or particles. More particularly, the field of the invention pertains to microfluidic devices and methods that utilize microfluidic trapping vortices for isolating cells or particles from a heterogeneous solution.
- the standard benchtop centrifuge is one of the most common instruments in the life science laboratory used ubiquitously for sample preparation in cell biology research and medical diagnostics. Typical sample preparation procedures require multiple centrifugation steps for cell labeling and washing, which can be a time consuming, laborious, and costly process for diagnostics and research. In fact, while assays themselves have widely been miniaturized and automated, sample preparation required for these assays has been identified as a key target for future automation.
- Centrifuges perform three critical sample preparation steps that make them so widely used: (i) separation of cells by size/density, (ii) concentration of cells, and (iii) solution exchange. Because centrifuges can perform such disparate functions, realizing these functions in a miniaturized platform has been challenging. Miniaturized microfluidic approaches often successfully implement one or two of these functions. For example, cell separation by size and density has been accomplished by using physical obstacles, external forces, or fluidic forces to guide particles to defined locations in a microchannel for collection at different outlets. While these methods may offer high resolution cell separation, the typical collected liquid volume is similar to the injected liquid volume—that is, no significant concentration is achieved.
- This large output volume can hinder downstream cell detection platforms that may require scanning large fields of view to observe the cells of interest or leads to dilution of biomolecules of interest if collected cells must be lysed.
- a method of concentration must be used in-line with the separation system to reduce the liquid volume for rapid detection and analysis.
- Park et al. discloses a structure that continuously focuses microparticles passing through the device.
- small diameter (7 ⁇ m diameter) polystyrene microspheres were run through a multi-orifice microchannel and trapping of these particles was not observed.
- Park et al. further observed that larger-sized particles tended to move away from the expanding channel regions where vortices were formed.
- U.S. Patent Application No. 2008/0318324 discloses a biochip for the high-throughput screening of cancer cells.
- the device uses effusive filtration to segregate tumor cells from a sample of bodily fluid.
- Effusive filtration refers to filtration configurations where the fluid is dispersed or redistributed by the filtration media or any morphological features inside the flow channel.
- the filtration media are side wall apertures having a width smaller than that of the cell.
- Chiu et al. discloses a 1-D channel having an expansion and constriction point to either slow down or speed up flow. Chiu et al.
- the fluid may become separated to form internal microvortices which aid in the filtration operation by altering fluid flow dynamics.
- the microvortices do not trap cells passing through the device. Rather, the apertures that line sections of the channel retain larger-sized cells by preventing the same from passing there through. While structures are disclosed that generate vortices for focusing or filtration aiding purposes, these structures are not used to selectively trap cells therein.
- a method of isolating cells includes providing a microfluidic device having at least one microfluidic channel coupled to an inlet and an outlet, the at least one microfluidic channel comprising at least one expansion region disposed along the length thereof, the at least one expansion region comprising an abrupt increase in a cross-sectional dimension of the at least one microfluidic channel configured to generate a vortex within the at least one expansion region in response to fluid flow.
- a solution containing a population of cells is flowed into the inlet. At least some of the cells are trapped within the vortex created within the at least one expansion region, the at least some of the cells having diameters ⁇ 10 ⁇ m. The trapped cells are released from the plurality expansion regions by reducing the flow rate of solution through the at least one microfluidic channel.
- a method of exchanging solution around isolated cells includes providing a microfluidic device having at least one microfluidic channel coupled to an inlet and an outlet, the at least one microfluidic channel comprising at least one expansion region disposed along the length thereof, the at least one expansion region comprising an abrupt increase in a cross-sectional dimension of the at least one microfluidic channel configured to generate a vortex within the at least one expansion region in response to fluid flow.
- a first solution containing a population of cells is flowed into the inlet. At least a portion of the cells are trapped within the vortex created within the at least one expansion region.
- One or more solutions different from the first solution are then flowed into the inlet while continuously maintaining the vortex containing the trapped cells.
- a method of trapping particles or cells by size includes providing a microfluidic device having at least one microfluidic channel coupled to an inlet and an outlet, the at least one microfluidic channel comprising at least one expansion region disposed along the length thereof, the at least one expansion region comprising an abrupt increase in a cross-sectional dimension of the at least one microfluidic channel configured to generate a vortex within the at least one expansion region in response to fluid flow.
- a solution containing a plurality cells or particles is flowed into the inlet.
- At least some of the cells or particles are trapped within the vortex created within the at least one expansion region, wherein the cells or particles having a size above threshold value are substantially trapped within the vortex and wherein cells or particles having a size below a threshold value substantially pass by the vortex.
- a microfluidic device in another embodiment, includes a substrate containing at least one microfluidic channel coupled to at least one inlet and an outlet, the at least one microfluidic channel comprising at least one expansion region disposed along the length of the at least one microfluidic channel, the at least one expansion region comprising an abrupt increase of at least 80 ⁇ m in a cross-sectional dimension of the at least one microfluidic channel, the at least one expansion region configured to generate a vortex within the at least one expansion region in response to fluid flow.
- a microfluidic system in another embodiment, includes a substrate containing at least one microfluidic channel coupled to at least one inlet and an outlet, the at least one microfluidic channel comprising at least one expansion region disposed along the length of the at least one microfluidic channel, the at least one expansion region comprising an abrupt increase in a cross-sectional dimension of the at least one microfluidic channel configured to generate a vortex within the at least one expansion region in response to fluid flow.
- the system includes at least one pump configured to pump fluid into the at least one inlet containing particles or cells.
- a computer is operatively coupled to the at least one pump and configured to adjust the flow rate of fluid passing through the at least one microfluidic channel.
- FIG. 1A illustrates a microfluidic system for isolating cells according to one embodiment.
- FIG. 1B illustrates a micro system for isolating cells according to another embodiment.
- FIG. 1C illustrates a schematic representation of a microfluidic channel with a single expansion region.
- FIGS. 1D-1G illustrate various geometries of the expansion region.
- FIG. 1H illustrates a plan view of a microfluidic channel with multiple expansion regions.
- FIG. 11 illustrates a cross-sectional view taken along the line A-A′ of FIG. 1H .
- FIG. 1J illustrates a schematic representation of a microfluidic channel with an expansion region according to another aspect of the invention.
- FIG. 2 illustrates a schematic view of a microfluidic device for isolating cells. Also included are graphical representations of forces acting on differing cell sizes at different points along the microfluidic device.
- FIG. 3 illustrates another microfluidic device for isolating cells having a parallel configuration.
- FIG. 4A schematically illustrates blood and cancer cells passing through a portion of the device having an expansion region that traps the larger cancer cells.
- a corresponding microscope image of a device containing several expansion regions is shown immediately below.
- FIG. 4B schematically illustrates a phosphate buffered saline (PBS) flush through the device of FIG. 4A showing evacuation of the red blood cells (RBCs) while cancer cells are retained in the expansion regions.
- PBS phosphate buffered saline
- FIGS. 4C-4F illustrates a blood sample spiked with HeLa cells passing through the microfluidic device of FIG. 3 at a Reynolds number (Rc) of 270.
- FIG. 4G illustrates a comparison of the capturing efficiency of the microfluidic device as a function of cell concentration.
- FIG. 5A illustrates a graph of the enrichment ratio (%) achieved with the microfluidic device at various blood concentrations.
- FIG. 5B illustrates a graph of the purity (%) achieved with the microfluidic device at various blood concentrations.
- FIG. 5C illustrates a graph of the capture efficiency (%) achieved with the microfluidic device at various blood concentrations.
- FIG. 6A illustrates a schematic representation of solution containing MCF7 cells (Solution A) wherein the cells are trapped within a vortex created within an expansion region.
- FIG. 6B illustrates a schematic representation of a first solution exchange occurring with Solution B that includes streptavidin-coated microspheres.
- FIG. 6C illustrates a schematic representation of the reaction of the MCF7 cells with the streptavidin-coated microspheres.
- FIG. 6D illustrates a schematic representation of a second solution exchanged conducted with Solution C (i.e., PBS) that acts as a wash.
- Solution C i.e., PBS
- FIG. 6E illustrates a microscopic image of MCF7 cells corresponding to FIG. 6A wherein cells orbit within a vortex created within an expansion region of the microfluidic device. Below left is a magnified view of the rectangular region. Below right is a magnified view of the square region.
- FIG. 6F illustrates a microscopic image corresponding to FIG. 6B .
- Below left is a magnified view of the rectangular region.
- Below right is a magnified view of the square region.
- FIG. 6G illustrates a microscopic image corresponding to FIG. 6C .
- Below left is a magnified view of the rectangular region.
- Below right is a magnified view of the square region.
- FIG. 6H illustrates a microscopic image corresponding to FIG. 6D . Below left is a magnified view of the rectangular region. Below right is a magnified view of the square region.
- FIG. 7 illustrates a microfluidic device according to another embodiment that includes three inlets coupled to three different solutions: cell sample, labeling agent, and wash.
- FIGS. 8A-8D illustrate the sequential steps of trapping, fluorescent solution exchange, reaction, and wash conducted on the device of FIG. 7 .
- FIG. 9 illustrates a fluorescent image of a cluster of cells that was sequentially trapped inside the fluid vortex, fixed with paraformaldehyde, permeabilized, and labeled with anti-Cytokeratin-PE & DAPI.
- FIG. 10 illustrates a graph of the number of streptavidin-coated microbeads bound per cell (MCF7 cells covered with biotinylated anti-EpCAM) as a function of time for both the microfluidic device and standard centrifugation.
- FIG. 11 illustrates a graph of the relative normalized frequency as a function of number of beads bound per cell for both the microfluidic device and standard centrifugation.
- FIG. 1A illustrates a microfluidic device 10 for isolating cells 12 from a heterogeneous solution containing cells 12 of different sizes. While the microfluidic device 10 is illustrated in FIG. 1A as being used for isolating cells 12 it should be understood that the microfluidic device 10 may also be used in connection with the isolation of particles (not shown). Thus, use of the term “cell” or “cells” herein should be interchangeable with particle or particles. As seen in FIG. 1A , the microfluidic device 10 includes a substrate 14 that contains a microfluidic channel 16 coupled to an inlet 18 and an outlet 20 . The dimensions of the microfluidic channel 16 may vary.
- the microfluidic channel may have a width of 50 ⁇ m and a height of 70 ⁇ m. Typical dimensions for the width of microfluidic channel 16 are in the range of 20 ⁇ m to 200 ⁇ m. Typical dimensions for the height of the microfluidic channel 16 are the range of 20 ⁇ m to 500 ⁇ m. The length may also vary but it generally is several centimeters in length (e.g., 4.5 cm).
- the substrate 14 may be formed from conventional materials used for microfluidic devices. These include glass, silicon, or polydimethylsiloxane (PDMS). For PDMS, soft lithography techniques may be used to create the microfluidic device 10 .
- PDMS polydimethylsiloxane
- a 4 inch silicon wafer is spin-coated with a 70 ⁇ m thick layer of a negative photoresist (KMPR 1050, Microchem), and exposed to UV-light through a designed Cr-photomask and developed.
- PDMS Sylgard 184, Dow Corning
- PDMS cast was separated from the mold and the inlet 18 and outlet 20 were punched with a pin vise (Pin vise set A, Technical Innovations Inc.).
- the now-punched PDMS layer was bonded to a slide glass by exposing both PDMS and a slide glass surfaces to air plasma (Plasma Cleaner, Harrick Plasma) to enclose the device.
- the inlet 18 actually includes two inlets—inlet 18 ′ and inlet 18 ′′.
- the first inlet 18 ′ is used to introduce the solution containing the heterogeneous population of cells 12 .
- the second inlet 18 ′′ is used to introduce a second, different solution.
- the second inlet 18 ′′ may be used to introduce a wash solution, label (e.g., fluorescent label, antibody, nucleic acid dye, fluorogenic substrate), or other chemical agent (e.g., fixation agent or permeabilization agent) into the microfluidic channel 16 .
- label e.g., fluorescent label, antibody, nucleic acid dye, fluorogenic substrate
- other chemical agent e.g., fixation agent or permeabilization agent
- the inlets 18 ′, 18 ′′ are coupled to respective pumps 22 , 24 .
- Each pump 22 , 24 can be used to deliver a set flow rate of the respective solution to the microfluidic device 10 .
- Any type of pump known to those skilled in the art may be used in connection with the invention. These include, without limitation, syringe pumps, pumps operating on pressurized air to pump fluid, peristaltic or positive displacement pumps.
- FIG. 1A illustrates syringe pumps 22 , 24 used with the microfluidic device 10 .
- a Harvard Apparatus, PHD 2000 syringe pump may be used to sustain an overall flow rate ranging between 10 ⁇ l/min and 4.5 ml/min.
- the settings of the pumps 22 , 24 are set to generate a flow rate through the microfluidic device 10 greater than 100 ⁇ l/min.
- FIG. 1A illustrates a computer 40 that can be used as part of a system 100 to control the microfluidic device 10 .
- the computer 40 typically contains at least one processor 42 therein that executes software residing in or stored on the computer 40 .
- the computer 40 also may include a monitor 44 that can be used to display various parameters of the microfluidic device 10 . These may include, for example, flow rates of pumps 22 , 24 , volume of fluid contained in pumps 22 , 24 , and other operational data.
- the computer 40 preferably interfaces with the pumps 22 , 24 such that the computer 40 is able to adjust the individual flow rates or operational states of the pumps 22 , 24 .
- the computer 40 may control the pumps 22 , 24 automatically using a preset algorithm or set of instructions stored in the computer 40 . Alternatively, control of the pumps 22 , 24 may be manually adjusted using an interface device commonly used with computers (e.g., keyboard, mouse, etc.)
- the computer 40 can ensure that the desired flow of solution of maintained in the microfluidic device 10 . For instance, when one pump 22 is slowed or even turned off, the flow rate of the second pump 24 is increased to ensure that the desired flow rate is maintained.
- FIG. 1B illustrates an alternative system 200 that uses a pressure driven pumping system 46 .
- the pumping system 46 uses a source of pressurized gas 48 along with regulators 50 to pump a first fluid 52 (e.g., wash) and second fluid 54 (e.g. blood) into the device 10 .
- first fluid 52 e.g., wash
- second fluid 54 e.g. blood
- liquid valves 56 , 58 are provided on the input and output, respectively, of the device 10 .
- a computer 40 is configured to control the pressure driven pumping system 46 and the liquid valves 56 , 58 .
- valve 56 may be used to open or close flow of either the first fluid 52 or the second fluid 54 to the device 10 .
- Valve 58 can be used to switch outlet flows between a waste receptacle 60 and a collection device 62 which may include, as an example, a 96 well plate.
- the microfluidic channel 16 includes a plurality of expansion regions 30 located at selected points along the length of the microfluidic channel 16 .
- the expansion regions 30 provide an abrupt increase in the width of the microfluidic channel 16 that, at or above certain threshold flow rates, create a detached boundary layer that causes the formation of vortices within each expansion region 30 . It is the vortices created within the expansion regions 30 that trap a subpopulation of cells 12 from a solution of heterogeneous cells 12 traveling through the microfluidic device 10 . These vortices, however, are different from the vortices created in the streamwise direction such as Dean vortices created in curved channel flows with inertia (See J.
- the most efficient trapping occurs for cells 12 having diameters greater than 15 ⁇ m. At diameters of less than 10 ⁇ m, trapping is less efficient (e.g. 5%). Thus, the diameters of the trapped cells 12 should be >10 ⁇ m in order for meaningful trapping to occur.
- the geometry of the expansion region 30 may vary.
- the expansion region 30 can be rectangular as illustrated in FIG. 1A but it may also include a square, triangle, polygonal, or semi-circular profile as illustrated in FIGS. 1C-1G .
- the trapping ability is better with the long side of the expansion region 30 being oriented parallel to the main microfluidic channel 16 .
- the leading wall 31 (illustrated in FIG. 1C ) of the expansion region 30 should be angled at or above 45° with respect to the flow direction of the upstream microfluidic channel 16 .
- FIG. 1C illustrates a single expansion region 30 along with the upstream microfluidic channel 16 .
- the leading wall 31 should be angled at or above 45° with respect to the axis of flow illustrated as dashed line A in FIG. 1C .
- the expansion region 30 is an abrupt expansion in cross-sectional dimension (e.g., width or height) compared to the cross-sectional dimension in the immediately upstream portion of microfluidic channel 16 .
- the leading wall 31 is angled just less than 90° which is well above the minimum 45° threshold value.
- the expansion region 30 also has a trailing wall 33 .
- the trailing wall 33 may be angled with respect to the flow direction A.
- the angle at which the trailing wall 33 is not significant may be any angle.
- the trailing wall 33 is angled a small amount which causes the trailing wall 33 to gradually taper back to the width of the microfluidic channel 16 .
- the expansion region 30 includes a leading wall 31 that is curved.
- the leading wall 31 initially starts a gradually divergence away from the upstream microfluidic channel 16 that increasingly diverges along the length of the leading wall 31 .
- various tangents taken along different points of the leading wall 31 will have significantly different angles compared to the axis of flow A.
- the angle ⁇ 1 is low and less than 45°.
- the angle ⁇ 2 is steep and more than 45°.
- an average angle ⁇ AVE which represents the average angle with respect to the axis of flow A along the entire length of the leading wall 31 should be greater than 45 ( ⁇ AVE >45°).
- FIG. 1H illustrates a plan view of several expansion regions 30 located along a length of a microfluidic channel 16 .
- FIG. 11 illustrates a cross-sectional view taken along the line A-A′ of FIG. 1H .
- Both FIGS. 1H and 1I illustrate various dimensions of the microfluidic channel 16 and expansion regions 30 .
- typical dimensions for the width (w) of microfluidic channel 16 is in the range of 20 ⁇ m to 200 ⁇ m.
- Typical dimensions for the height (H) of the microfluidic channel 16 are the range of 20 ⁇ m to 500 ⁇ m.
- the expansion region 30 may extend a distance (x) that is in the range between 80 ⁇ m and 800 ⁇ m but should be at least 80 ⁇ m.
- the expansion region 30 may extend a distance (y) that is in the range of 200 ⁇ m to 2 mm. Adjacent expansion regions 30 may be separated by distances (z) typically greater than 20 ⁇ m. In some embodiments, there may be a single expansion region 30 such that there is no adjacent expansion region 30 .
- the cross-sectional profile of the microfluidic channel 16 may be substantially rectangular, trapezoidal, or square. The microfabrication process can lead to slightly trapezoidal cross-sections or corners that are slightly rounded. The channels 16 may also have circular or semi-circular cross sections although current fabrication techniques do not produce these geometries. These variations are intended to be covered by the methods and devices described herein.
- the expansion regions 30 may be disposed on opposing sides of the microfluidic channel 16 .
- This enables a single microfluidic channel 16 to have greater capturing capabilities.
- this configuration enables a staggered arrangement of expansion regions 30 when multiple channels 16 are aligned in a parallel configuration. That is to say, adjacent microfluidic channels 16 can be closely packed together because expansion regions 30 are offset from one another and interleave with expansion regions 30 on adjacent microfluidic channels 16 as seen in FIG. 3 . Still referring to FIG.
- the larger-sized cells 12 are trapped within the expansion regions 30 while the smaller-sized cells 12 are not trapped and continue to flow down the microfluidic channel 16 where they exit via outlet 20 .
- Larger-sized cells 12 (those illustrated in the expansion regions 30 ) are trapped within a vortex flow that is created within the expansion regions 30 .
- Smaller-sized cells 12 due to their size they are not trapped within the vortex flow and pass out of the expansion regions 30 .
- smaller-sized cells 12 are not trapped by the vortex in the expansion regions 30 and continue to flow downstream in the microfluidic channel 16 .
- FIG. 2 illustrates a microfluidic device 10 for isolating cells 12 from a heterogeneous solution containing cells 12 of different sizes as well as corresponding flows within the microfluidic channel 16 and expansion regions 30 .
- FIG. 2 illustrates magnified views of three regions of the microfluidic channel 16 and expansion regions 30 as identified by views A, B, and C.
- a heterogeneous population of different sized cells 12 is pumped into the device via one of the syringe pumps 22 , 24 .
- the other syringe pump may contain a wash or other solution such as PBS. Initially, as seen in view A, the cells 12 are randomly dispersed is the y-direction.
- the cells 12 experience two counteracting forces—a shear gradient lift force (F L shear gradient) that acts on the cells 12 to move the same toward the walls of the microfluidic channel 16 and a wall effect lift force (F L wall effect) that repels cells 12 away from the walls of the microfluidic channel 16 .
- F L shear gradient a shear gradient lift force
- F L wall effect a wall effect lift force
- X eq is defined as the distance between the center of cells 12 and the wall of the microfluidic channel 16 .
- F L shear gradient force scales with the cube of the cell diameter (a), causing larger cells 12 to experience a larger F L shear gradient force.
- Size-dependent lateral migration drives cells 12 across streamlines past the detached boundary (separatrix) toward the vortex core where the cells 12 remain isolated and orbiting in the vortex. This enables size-selective trapping, as below a size cutoff, cells do not migrate at a sufficient rate to pass the separatrix and remain in focused streams, flowing out of the outlet 20 .
- FIG. 3 illustrates another embodiment of a microfluidic device 10 for isolating cells 12 that includes a plurality of channels 16 coupled to an inlet 18 and an outlet 20 .
- FIG. 3 illustrates eight (8) separate channels 16 that arranged generally parallel to one another.
- Each microfluidic channel 16 has ten (10) separate expansion regions 30 .
- any number of channels 16 may be used.
- Spacing between adjacent expansion regions 30 along a single microfluidic channel 16 may vary but 1 mm spacing has been found to work. Additional channels 16 may be added to create a massively parallel device 10 .
- the channels 16 are straight with expansion regions 30 on adjacent channels 16 being staggered with respect to one other. This design enables adjacent channels 16 to be placed close to one another, thereby reducing the overall footprint of the microfluidic device 10 . While FIG. 3 illustrates an array of channels 16 in a two-dimensional layout it should be understood that the array of channels 16 could also be configured in a three-dimensional layout. The three-dimensional configuration would allow even more throughput.
- the microfluidic channel 16 is a rectangular high-aspect ratio channel with a width of 50 ⁇ m and a height of 70 ⁇ m.
- the inlet 18 includes a first inlet 18 ′ for the sample containing the cells 12 and a second inlet 18 ′′ that contains PBS or other wash solution.
- the duel inlet 18 ′, 18 ′′ arrangement allows for easy and rapid solution exchange within the microfluidic device 10 , providing, for example, a means to flush un-trapped cells 12 and to enhance the final enrichment ratio and the purity of the collected samples.
- the length of the microfluidic device 10 was several centimeters long.
- the expansion regions 30 were placed in an alternating pattern in order to place the maximum number of expansion regions 30 in a given compact footprint. In the device of FIG. 3 , the expansion regions were squares having dimensions of 400 ⁇ m ⁇ 400 ⁇ m.
- the cells 12 may be released from the expansion regions 30 by allowing the vortices to reduce in size and ultimately dissipate. This can be accomplished by lowering the input flow rate (e.g., reduce flow rate(s) of pumps 22 , 24 ). The reduced flow rate reduced the vortex size allowing the cells 12 trapped therein to be released into the flow of the microfluidic channel 16 and carried out the outlet 20 of the device. A flow rate of around 4 ml/minute has been found to work best with the device of FIG. 3 . Alternatively, the flow rate may be rapidly decreased to substantially zero to stop the flow of fluid through the microfluidic device 10 . In this alternative, the cells 12 can be collected on-chip rather than off-chip.
- the microfluidic device 10 of FIG. 3 was applied to separating and concentrating cancer cells (diameter of 20 micrometers) from normal human blood cells (diameters range from 2 to 15 micrometers) to demonstrate utility for size-based enrichment and concentration in a high-throughput manner.
- Enriching and concentrating cancer cells from blood is particularly important for clinical diagnostics as circulating tumor cells (CTCs) can provide real-time information on patient status and monitoring of cancer therapies. Isolating viable CTCs from blood in a quick, effective and label-free approach remains a significant technical challenge—CTCs are rare events at rates as low as one cell per one billion blood cells.
- This device 10 addresses the need for rare cell enrichment with a massively parallel device that processes liquid volumes in the mL/min range, enriches target cells through size and density-based separation, and releases captured cells into a smaller concentrated volume.
- fluorescently-labeled breast cancer cells MCF-7
- MCF7 breast cancer cells were cultured in media containing DMEM supplemented with 10% FBS, 1% bovine insulin, and 1% penicillin/streptomycin were trypsinized and resuspended before use. Blood was collected from healthy human volunteers by a trained physician and diluted in PBS to 5-20% for experiments.
- Spiked MCF-7 cells included single cells and 2-4 cell clusters, as clustered cells have been shown to be present at significant levels in clinical samples.
- Blood and cancer cells were observed to enter and orbit in the vortices during the injection step as illustrated in the schematic view of a single expansion region 30 in the upper panel of FIG. 4A .
- the lower panel of FIG. 4A illustrates a microscopic image showing a trapped cancer cell along with red blood cells contained in the expansion region 30 . Red blood cells were observed to enter vortices even though particles of similar size did not migrate into vortices in experiments with dilute samples.
- the high cell concentration induces collisions and hydrodynamic disturbances between cells that lead to cross-stream migration and entrance into vortices.
- each expansion region 30 can maintain. After the vortex occupies the entire expansion region 30 a maximum of ⁇ 40 single MCF7 cells can be maintained over a range of higher flow rates. For most spiking experiments conditions were kept well below this maximum.
- the vortex-trapped cells were “washed” with PBS without disrupting the vortices. This is illustrated in the upper panel of FIG. 4B .
- the lower panel of FIG. 4B illustrates a microscopic image showing the still trapped cancer cell after a PBS wash solution has been introduced to remove the smaller and denser RBCs.
- the microfluidic device 10 performs well when quantifying key metrics for target cell concentration, enrichment, and purity.
- 10 mL volume blood samples (n ⁇ 6 samples) of 5% v/v blood (i.e., 0.5 mL whole blood or ⁇ 2.5 billion blood cells) spiked with ⁇ 500 cancer cells were concentrated to a final volume of less than 200 mL (20-fold volumetric concentration) with relatively little blood cell contamination in ⁇ 3 min.
- This high level of enrichment leads to high purity of the cancer cells in the 200 mL final volume: ⁇ 40% as seen in FIG.
- Cells captured in the microfluidic device 10 maintained high levels of viability. No significant changes were observed in cell viability (90.1% vs. 90.3% initial) after injecting cells through the device as determined by a fluorescent live/dead assay. Viable cells may be important for some sample preparation applications.
- Cells captured and released from the microfluidic device 10 are available for standard molecular assays such as immunostaining. To this end, unlabeled spiked blood samples were enriched with the microfluidic device 10 . Cancer cells were then released and labeled in a microwell. Cancer cells stained positive for Cytokeratin-PE and DAPI and negative for CD45. This ability to enrich on one device but transfer cells in a small volume for further processing offers significant advantages for rare single cell analysis.
- FIGS. 4C-4F illustrate the results of similar enrichment of a blood sample spiked with HeLa cells using the microfluidic device 10 of FIG. 3 at a Reynolds number (Rc) of 270.
- the microfluidic device 10 is flushed with PBS wash once the HeLa cells were captured in the expansion regions 30 .
- FIG. 4G illustrates a comparison of the capturing efficiency of the microfluidic device 10 as a function of cell concentration.
- the number of cells indicates the number of spiked HeLa cells processed through the microfluidic device 10 .
- the microfluidic device 10 was also used to effectively label cells for specific molecular markers.
- traditional centrifugation cell samples are labeled for specific markers through a series of labeling and washing steps. This includes incubating the cells with labeling reagents in a centrifuge tube, concentrating the cells into a pellet with a benchtop centrifuge, removing the supernatant layer containing unbound labeling reagents through manual aspiration, and manually resuspending the cells in a new medium. These operations were performed within the microfluidic device 10 by trapping the cells within fluid vortices and sequentially exposing trapped orbiting cells to labeling reagents, followed by a PBS wash solution. Labeled cells were then released within a small volume into a collection vial by reducing flow.
- FIGS. 6A-6D illustrate, respectively, the trapping ( FIG. 6A ), first solution exchange ( FIG. 6B ), reaction ( FIG. 6C ), and second solution exchange ( FIG. 6D ).
- FIGS. 6E-6H illustrate, respectively, microscope images corresponding to FIGS. 6A-6D of actual MCF7 cells incubated with biotinylated EpCAM that were injected into the microfluidic device 10 . As seen in FIG. 6E , cells are trapped in the vortex, undergoing a constant rotating and orbiting motion.
- FIG. 6F illustrates the first solution exchange with streptavidin-coated microspheres. The streptavidin-coated microspheres enter the expansion region 30 .
- FIG. 6G illustrates the continuous reaction of the streptavidin-coated microspheres with the MCF7 cells.
- FIG. 6H illustrates a solution exchange with a second solution (i.e., PBS wash).
- the PBS wash removes unbound microspheres (arrow A).
- the cells are released from vortex traps by lowering the flow rate through the microfluidic device 10 wherein the cells are collected into a 96-well-plate for characterization.
- Arrows B in FIG. 6H point to particles that are increasingly bound to the cell over 2 minutes.
- Fast labeling is aided by cells that rotate and orbit in the fluid vortex such that they are exposed to a constantly refreshed milieu of molecular labels.
- strong convection of labeling reagents in the vortex leads to a very small depleted region of reagents near the cell surface and a strong gradient driving more reagents to the cell surface.
- This fast labeling was observed by examining the binding of streptavidin-coated microspheres to biotinylated anti-EpCAM antibodies on the cell surface ( FIGS. 6A-6H ). It was found that the cells in the microfluidic device 10 accumulated the same number of microbeads in 5 minutes that cells prepared with the standard protocol accumulated in 30 minutes. Further, after 30 minutes, cells labeled with the microfluidic device 10 on average had twice the number of microbeads bound per cell compared to standard methods.
- the microfluidic device 10 included three inlets 18 ′, 18 ′′, and 18 ′′′.
- One inlet 18 ′ was coupled a syringe pump 22 that was used to deliver the cell sample.
- the second syringe pump 24 was used to deliver the fluorescent agent.
- the third syringe pump 26 is used to deliver wash (PBS). Size-based trapping of cancer cells from blood, sequential fluorescent labeling, and analysis of released cells were conducted in ⁇ 1 hour.
- Diluted human blood (10 mL) spiked with cancer cells was injected into the microfluidic device 10 for ⁇ 3 min to enrich the cancer cells. Trapped cells were sequentially prepared with a fixation agent (paraformaldehyde) and permeabilization agent and stained with fluorescent antibodies (anti-Cytokeratin-PE & DAPI) for 20 min. The sequence of trapping, first solution exchange, reaction, and second solution exchange is seen in FIGS. 8A-8D . Cells were then washed with PBS for ⁇ 1 min, and collected into a 96-well-plate for characterization. Collected cells labeled positive for cytokeratin and DAPI, indicating the success of sequential sample preparation as illustrated in FIG.
- FIG. 9 which shows a fluorescent image of a cluster of cells that was sequentially trapped inside the fluid vortex, fixed with paraformaldehyde, permeabilized, and labeled with anti-Cytokeratin-PE & DAPI.
- MCF7 cells covered with biotinylated anti-EpCAM are coated with streptavidin conjugated microbeads in ⁇ 5 minutes at the same level as a standard off-chip protocol after 30 minutes.
- FIG. 1 A 1 illustrates uniform labeling with microbeads over the cell population after 30 minutes.
- the microfluidic device 10 centrifuge-on-chip results in a larger number of beads bound per cell. The results above demonstrate a complete route to automation of all of the sample preparation processes required for cell analysis in a single simple platform.
- the devices 10 and methods described herein are useful for inexpensive and rapid circulating tumor cell (CTC) analysis.
- CTC detection and enumeration is a valuable and promising diagnostic tool for monitoring breast cancer status and outcome.
- CTCs are tumor-derived cells that spread via the bloodstream and can reflect the aggressiveness of a tumor.
- CTCs are rare events at rates as low as one cell per one billion cells.
- CTC isolation thus presents a significant technological challenge.
- the devices 10 and methods described herein can exploit the cell size difference between CTCs and blood cells (CTCs are 2-4 times larger than RBCs) to isolate viable CTCs from whole blood in a label-free manner.
- Other potential applications of the devices 10 and methods include prenatal testing that involves the isolation of fetal cells from maternal blood cells. Fetal cells of interest can be isolated without labeling or external bulk machines.
- microfluidic device 10 has particular application for isolating CTCs, other applications include concentrating cells 12 obtained from a sample.
- cells 12 of interest having a size that enables trapping within expansion regions 30 can be captured then released into a sample in concentrated form.
- cells 12 contained in a biological source of fluid like urine, pleural fluid, and peritoneal washes can be run through the microfluidic device 10 to concentrate cells 12 contained therein.
- the microfluidic device 10 is well suited for concentrating cells 12 .
- the microfluidic device 10 can concentrate cells 12 more than ten (10) or twenty (20) times the concentration of the cells 12 in the initial solution.
Abstract
A method of isolating cells includes providing a microfluidic device having at least one microfluidic channel coupled to an inlet and an outlet, the at least one microfluidic channel comprises at least one expansion region disposed along the length thereof The at least one expansion region is an abrupt increase in a cross-sectional dimension of the at least one microfluidic channel configured to generate a vortex within the at least one expansion region in response to fluid flow. A solution containing a population of cells at least some of which have diameters ≧10 μm flows into the inlet. A portion of cells is trapped within vortex created within the at least one expansion region. The trapped cells may then released from the expansion region.
Description
- This Application is a continuation of U.S. patent application Ser. No. 14/948,119, filed Nov. 20, 2015, which itself is a continuation of U.S. patent application Ser. No. 14/819,302 filed on Aug. 5, 2015, which itself is a divisional of U.S. patent application Ser. No. 13/823,112 filed on Mar. 14, 2013, now issued as U.S. Pat. No. 9,133,499, which is a U.S. National Stage filing under 35 U.S.C. §371 of International Application No. PCT/US2011/051224, filed Sep. 12, 2011, which claims priority to U.S. Provisional Patent Application No. 61/382,840 filed on Sep. 14, 2010. The contents of the aforementioned applications are hereby incorporated herein by reference in their entirety. Priority to the aforementioned applications are hereby expressly claimed in accordance with 35 U.S.C. §§119, 120, 365 and 371 and any other applicable statutes.
- The field of the invention generally relates to microfluidic devices and methods for the isolation and sorting of cells or particles. More particularly, the field of the invention pertains to microfluidic devices and methods that utilize microfluidic trapping vortices for isolating cells or particles from a heterogeneous solution.
- The standard benchtop centrifuge is one of the most common instruments in the life science laboratory used ubiquitously for sample preparation in cell biology research and medical diagnostics. Typical sample preparation procedures require multiple centrifugation steps for cell labeling and washing, which can be a time consuming, laborious, and costly process for diagnostics and research. In fact, while assays themselves have widely been miniaturized and automated, sample preparation required for these assays has been identified as a key target for future automation.
- Centrifuges perform three critical sample preparation steps that make them so widely used: (i) separation of cells by size/density, (ii) concentration of cells, and (iii) solution exchange. Because centrifuges can perform such disparate functions, realizing these functions in a miniaturized platform has been challenging. Miniaturized microfluidic approaches often successfully implement one or two of these functions. For example, cell separation by size and density has been accomplished by using physical obstacles, external forces, or fluidic forces to guide particles to defined locations in a microchannel for collection at different outlets. While these methods may offer high resolution cell separation, the typical collected liquid volume is similar to the injected liquid volume—that is, no significant concentration is achieved. This large output volume can hinder downstream cell detection platforms that may require scanning large fields of view to observe the cells of interest or leads to dilution of biomolecules of interest if collected cells must be lysed. Thus, a method of concentration must be used in-line with the separation system to reduce the liquid volume for rapid detection and analysis.
- There are a variety of techniques for concentrating particles and cells in localized regions with microfluidic systems. Of these, mechanical traps are the most commonly used method that anchors particles and cells to a physical structure and enables multistep perfusion of reagents to perform cell assays on-chip via solution exchange. Often, however, it may be important to release particles and cells on-demand for further downstream analysis. Although successful at concentration and release, cells immobilized in these trap-and-release systems can squeeze through traps and become damaged when operated at higher volumetric throughput, thereby limiting concentration factors to below what is necessary for concentration of rare cells or dilute cell solutions. Thus, a general purpose miniaturized tool that recapitulates all of the functions and flexibility of a traditional centrifuge has yet to be achieved.
- The formation of vortices within a microfluidic structure has been used for focusing and filtration enhancement. For example, Park et al. (Jae-Sung et al., Continuous focusing of microparticles using inertial lift force and vorticity via multi-orifice microfluidic channels, Lab Chip, 9, 939-948 (2009)) discloses a microfluidic device used in experiments that focuses rigid microparticles using a series of suddenly expanding and contracting channels. At certain flow rates, vortices are formed within the expanded channels. The vortices formed within the expanded channels induce lateral particles migration like a tubular pinch effect. By having a series of these expanded channels along a length of a microchannel, rigid microparticles are able to gradually migrate (i.e., are focused) to opposing sides of the microchannel. Importantly, however, the expanded channels do not trap the particles. Instead, Park et al. discloses a structure that continuously focuses microparticles passing through the device. In Park et al., small diameter (7 μm diameter) polystyrene microspheres were run through a multi-orifice microchannel and trapping of these particles was not observed. Park et al. further observed that larger-sized particles tended to move away from the expanding channel regions where vortices were formed. Park et al. also discloses that particles in the sample should be like rigid spheres for maximal value of the inertial lift force which obviously runs counter to its use with living cells that, by their nature, are generally deformable. Structurally, Park et al. discloses rather small-sized expanding channels that expand outward a distance of around 80 μm with respect to the upstream contracting channel. Further, the length of the expanding channels is also small, disclosed as being 200 μm.
- U.S. Patent Application No. 2008/0318324 (Chiu et al.) discloses a biochip for the high-throughput screening of cancer cells. The device uses effusive filtration to segregate tumor cells from a sample of bodily fluid. Effusive filtration refers to filtration configurations where the fluid is dispersed or redistributed by the filtration media or any morphological features inside the flow channel. In Chiu et al., the filtration media are side wall apertures having a width smaller than that of the cell. In one embodiment, Chiu et al. discloses a 1-D channel having an expansion and constriction point to either slow down or speed up flow. Chiu et al. discloses that at high velocities the fluid may become separated to form internal microvortices which aid in the filtration operation by altering fluid flow dynamics. The microvortices, however, do not trap cells passing through the device. Rather, the apertures that line sections of the channel retain larger-sized cells by preventing the same from passing there through. While structures are disclosed that generate vortices for focusing or filtration aiding purposes, these structures are not used to selectively trap cells therein.
- In one embodiment of the invention, a method of isolating cells includes providing a microfluidic device having at least one microfluidic channel coupled to an inlet and an outlet, the at least one microfluidic channel comprising at least one expansion region disposed along the length thereof, the at least one expansion region comprising an abrupt increase in a cross-sectional dimension of the at least one microfluidic channel configured to generate a vortex within the at least one expansion region in response to fluid flow. A solution containing a population of cells is flowed into the inlet. At least some of the cells are trapped within the vortex created within the at least one expansion region, the at least some of the cells having diameters ≧10 μm. The trapped cells are released from the plurality expansion regions by reducing the flow rate of solution through the at least one microfluidic channel.
- In another embodiment of the invention, a method of exchanging solution around isolated cells includes providing a microfluidic device having at least one microfluidic channel coupled to an inlet and an outlet, the at least one microfluidic channel comprising at least one expansion region disposed along the length thereof, the at least one expansion region comprising an abrupt increase in a cross-sectional dimension of the at least one microfluidic channel configured to generate a vortex within the at least one expansion region in response to fluid flow. A first solution containing a population of cells is flowed into the inlet. At least a portion of the cells are trapped within the vortex created within the at least one expansion region. One or more solutions different from the first solution are then flowed into the inlet while continuously maintaining the vortex containing the trapped cells.
- In another embodiment of the invention, a method of trapping particles or cells by size includes providing a microfluidic device having at least one microfluidic channel coupled to an inlet and an outlet, the at least one microfluidic channel comprising at least one expansion region disposed along the length thereof, the at least one expansion region comprising an abrupt increase in a cross-sectional dimension of the at least one microfluidic channel configured to generate a vortex within the at least one expansion region in response to fluid flow. A solution containing a plurality cells or particles is flowed into the inlet. At least some of the cells or particles are trapped within the vortex created within the at least one expansion region, wherein the cells or particles having a size above threshold value are substantially trapped within the vortex and wherein cells or particles having a size below a threshold value substantially pass by the vortex.
- In another embodiment of the invention, a microfluidic device includes a substrate containing at least one microfluidic channel coupled to at least one inlet and an outlet, the at least one microfluidic channel comprising at least one expansion region disposed along the length of the at least one microfluidic channel, the at least one expansion region comprising an abrupt increase of at least 80 μm in a cross-sectional dimension of the at least one microfluidic channel, the at least one expansion region configured to generate a vortex within the at least one expansion region in response to fluid flow.
- In another embodiment of the invention, a microfluidic system includes a substrate containing at least one microfluidic channel coupled to at least one inlet and an outlet, the at least one microfluidic channel comprising at least one expansion region disposed along the length of the at least one microfluidic channel, the at least one expansion region comprising an abrupt increase in a cross-sectional dimension of the at least one microfluidic channel configured to generate a vortex within the at least one expansion region in response to fluid flow. The system includes at least one pump configured to pump fluid into the at least one inlet containing particles or cells. A computer is operatively coupled to the at least one pump and configured to adjust the flow rate of fluid passing through the at least one microfluidic channel.
-
FIG. 1A illustrates a microfluidic system for isolating cells according to one embodiment. -
FIG. 1B illustrates a micro system for isolating cells according to another embodiment. -
FIG. 1C illustrates a schematic representation of a microfluidic channel with a single expansion region. -
FIGS. 1D-1G illustrate various geometries of the expansion region. -
FIG. 1H illustrates a plan view of a microfluidic channel with multiple expansion regions. -
FIG. 11 illustrates a cross-sectional view taken along the line A-A′ ofFIG. 1H . -
FIG. 1J illustrates a schematic representation of a microfluidic channel with an expansion region according to another aspect of the invention. -
FIG. 2 illustrates a schematic view of a microfluidic device for isolating cells. Also included are graphical representations of forces acting on differing cell sizes at different points along the microfluidic device. -
FIG. 3 illustrates another microfluidic device for isolating cells having a parallel configuration. -
FIG. 4A schematically illustrates blood and cancer cells passing through a portion of the device having an expansion region that traps the larger cancer cells. A corresponding microscope image of a device containing several expansion regions is shown immediately below. -
FIG. 4B schematically illustrates a phosphate buffered saline (PBS) flush through the device ofFIG. 4A showing evacuation of the red blood cells (RBCs) while cancer cells are retained in the expansion regions. A corresponding microscope image of a device containing several expansion regions is shown immediately below. -
FIGS. 4C-4F illustrates a blood sample spiked with HeLa cells passing through the microfluidic device ofFIG. 3 at a Reynolds number (Rc) of 270.FIG. 4C illustrates an image taken at t=0 seconds.FIG. 4D illustrates an image taken at t=9 seconds.FIG. 4E illustrates an image taken at t=17 seconds.FIG. 4F illustrates an image taken at t=18 seconds. HeLa cells are seen trapped within the vortex created within the expansion region. -
FIG. 4G illustrates a comparison of the capturing efficiency of the microfluidic device as a function of cell concentration. -
FIG. 5A illustrates a graph of the enrichment ratio (%) achieved with the microfluidic device at various blood concentrations. -
FIG. 5B illustrates a graph of the purity (%) achieved with the microfluidic device at various blood concentrations. -
FIG. 5C illustrates a graph of the capture efficiency (%) achieved with the microfluidic device at various blood concentrations. -
FIG. 6A illustrates a schematic representation of solution containing MCF7 cells (Solution A) wherein the cells are trapped within a vortex created within an expansion region. -
FIG. 6B illustrates a schematic representation of a first solution exchange occurring with Solution B that includes streptavidin-coated microspheres. -
FIG. 6C illustrates a schematic representation of the reaction of the MCF7 cells with the streptavidin-coated microspheres. -
FIG. 6D illustrates a schematic representation of a second solution exchanged conducted with Solution C (i.e., PBS) that acts as a wash. -
FIG. 6E illustrates a microscopic image of MCF7 cells corresponding toFIG. 6A wherein cells orbit within a vortex created within an expansion region of the microfluidic device. Below left is a magnified view of the rectangular region. Below right is a magnified view of the square region. -
FIG. 6F illustrates a microscopic image corresponding toFIG. 6B . Below left is a magnified view of the rectangular region. Below right is a magnified view of the square region. -
FIG. 6G illustrates a microscopic image corresponding toFIG. 6C . Below left is a magnified view of the rectangular region. Below right is a magnified view of the square region. -
FIG. 6H illustrates a microscopic image corresponding toFIG. 6D . Below left is a magnified view of the rectangular region. Below right is a magnified view of the square region. -
FIG. 7 illustrates a microfluidic device according to another embodiment that includes three inlets coupled to three different solutions: cell sample, labeling agent, and wash. -
FIGS. 8A-8D illustrate the sequential steps of trapping, fluorescent solution exchange, reaction, and wash conducted on the device ofFIG. 7 . -
FIG. 9 illustrates a fluorescent image of a cluster of cells that was sequentially trapped inside the fluid vortex, fixed with paraformaldehyde, permeabilized, and labeled with anti-Cytokeratin-PE & DAPI. -
FIG. 10 illustrates a graph of the number of streptavidin-coated microbeads bound per cell (MCF7 cells covered with biotinylated anti-EpCAM) as a function of time for both the microfluidic device and standard centrifugation. -
FIG. 11 illustrates a graph of the relative normalized frequency as a function of number of beads bound per cell for both the microfluidic device and standard centrifugation. -
FIG. 1A illustrates amicrofluidic device 10 for isolatingcells 12 from a heterogeneoussolution containing cells 12 of different sizes. While themicrofluidic device 10 is illustrated inFIG. 1A as being used for isolatingcells 12 it should be understood that themicrofluidic device 10 may also be used in connection with the isolation of particles (not shown). Thus, use of the term “cell” or “cells” herein should be interchangeable with particle or particles. As seen inFIG. 1A , themicrofluidic device 10 includes asubstrate 14 that contains amicrofluidic channel 16 coupled to aninlet 18 and anoutlet 20. The dimensions of themicrofluidic channel 16 may vary. As an example, the microfluidic channel may have a width of 50 μm and a height of 70 μm. Typical dimensions for the width ofmicrofluidic channel 16 are in the range of 20 μm to 200 μm. Typical dimensions for the height of themicrofluidic channel 16 are the range of 20 μm to 500 μm. The length may also vary but it generally is several centimeters in length (e.g., 4.5 cm). Thesubstrate 14 may be formed from conventional materials used for microfluidic devices. These include glass, silicon, or polydimethylsiloxane (PDMS). For PDMS, soft lithography techniques may be used to create themicrofluidic device 10. In the PDMS embodiment, for mold fabrication, a 4 inch silicon wafer is spin-coated with a 70 μm thick layer of a negative photoresist (KMPR 1050, Microchem), and exposed to UV-light through a designed Cr-photomask and developed. PDMS (Sylgard 184, Dow Corning) was cast on to the prepared mold and degassed. Cured - PDMS cast was separated from the mold and the
inlet 18 andoutlet 20 were punched with a pin vise (Pin vise set A, Technical Innovations Inc.). The now-punched PDMS layer was bonded to a slide glass by exposing both PDMS and a slide glass surfaces to air plasma (Plasma Cleaner, Harrick Plasma) to enclose the device. - In the embodiment of
FIG. 1A , theinlet 18 actually includes two inlets—inlet 18′ andinlet 18″. Thefirst inlet 18′ is used to introduce the solution containing the heterogeneous population ofcells 12. Thesecond inlet 18″ is used to introduce a second, different solution. As explained in more detail below, thesecond inlet 18″ may be used to introduce a wash solution, label (e.g., fluorescent label, antibody, nucleic acid dye, fluorogenic substrate), or other chemical agent (e.g., fixation agent or permeabilization agent) into themicrofluidic channel 16. - As seen in
FIG. 1A , theinlets 18′, 18″ are coupled torespective pumps pump microfluidic device 10. Any type of pump known to those skilled in the art may be used in connection with the invention. These include, without limitation, syringe pumps, pumps operating on pressurized air to pump fluid, peristaltic or positive displacement pumps.FIG. 1A illustrates syringe pumps 22, 24 used with themicrofluidic device 10. For example, a Harvard Apparatus,PHD 2000 syringe pump may be used to sustain an overall flow rate ranging between 10 μl/min and 4.5 ml/min. Typically, the settings of thepumps microfluidic device 10 greater than 100 μl/min. -
FIG. 1A illustrates acomputer 40 that can be used as part of asystem 100 to control themicrofluidic device 10. Thecomputer 40 typically contains at least oneprocessor 42 therein that executes software residing in or stored on thecomputer 40. Thecomputer 40 also may include amonitor 44 that can be used to display various parameters of themicrofluidic device 10. These may include, for example, flow rates ofpumps pumps computer 40 preferably interfaces with thepumps computer 40 is able to adjust the individual flow rates or operational states of thepumps computer 40 may control thepumps computer 40. Alternatively, control of thepumps - During solution exchange operations, the
computer 40 can ensure that the desired flow of solution of maintained in themicrofluidic device 10. For instance, when onepump 22 is slowed or even turned off, the flow rate of thesecond pump 24 is increased to ensure that the desired flow rate is maintained. -
FIG. 1B illustrates analternative system 200 that uses a pressure drivenpumping system 46. Thepumping system 46 uses a source ofpressurized gas 48 along withregulators 50 to pump a first fluid 52 (e.g., wash) and second fluid 54 (e.g. blood) into thedevice 10. In thissystem 200,liquid valves device 10. Acomputer 40 is configured to control the pressure drivenpumping system 46 and theliquid valves valve 56 may be used to open or close flow of either thefirst fluid 52 or thesecond fluid 54 to thedevice 10.Valve 58 can be used to switch outlet flows between awaste receptacle 60 and acollection device 62 which may include, as an example, a 96 well plate. - As seen in
FIG. 1A , themicrofluidic channel 16 includes a plurality ofexpansion regions 30 located at selected points along the length of themicrofluidic channel 16. Theexpansion regions 30 provide an abrupt increase in the width of themicrofluidic channel 16 that, at or above certain threshold flow rates, create a detached boundary layer that causes the formation of vortices within eachexpansion region 30. It is the vortices created within theexpansion regions 30 that trap a subpopulation ofcells 12 from a solution ofheterogeneous cells 12 traveling through themicrofluidic device 10. These vortices, however, are different from the vortices created in the streamwise direction such as Dean vortices created in curved channel flows with inertia (See J. Wang et al., Vortex-assisted DNA Delivery, Lab Chip, 2010, 10, 2057-2061 (2010)) or vortices created due to asymmetrically structured microchannels (See Stott et al., Isolation of Circulating Tumor Cells Using a Microvortex-Generating Herringbone-Chip, Proc Natl. Acad. Sci. 107(43):18392-7 (2010)). As explained in more detail below,cells 12 above a certain threshold or cutoff size (which depends on the flow rate and geometry of the microfluidic device 10) enter theexpansion regions 30 and get caught or trapped within the re-circulating vortices.Cells 12 that are below the threshold size do not get caught and continue to flow downstream in themicrofluidic device 10. Generally, the most efficient trapping occurs forcells 12 having diameters greater than 15 μm. At diameters of less than 10 μm, trapping is less efficient (e.g. 5%). Thus, the diameters of the trappedcells 12 should be >10 μm in order for meaningful trapping to occur. The geometry of theexpansion region 30 may vary. For example, theexpansion region 30 can be rectangular as illustrated inFIG. 1A but it may also include a square, triangle, polygonal, or semi-circular profile as illustrated inFIGS. 1C-1G . For rectangular-shapedexpansion regions 30 the trapping ability is better with the long side of theexpansion region 30 being oriented parallel to the mainmicrofluidic channel 16. Generally, the leading wall 31 (illustrated inFIG. 1C ) of theexpansion region 30 should be angled at or above 45° with respect to the flow direction of the upstreammicrofluidic channel 16. -
FIG. 1C illustrates asingle expansion region 30 along with the upstreammicrofluidic channel 16. As stated above, the leadingwall 31 should be angled at or above 45° with respect to the axis of flow illustrated as dashed line A inFIG. 1C . In this regard, theexpansion region 30 is an abrupt expansion in cross-sectional dimension (e.g., width or height) compared to the cross-sectional dimension in the immediately upstream portion ofmicrofluidic channel 16. In the embodiment ofFIG. 1C , the leadingwall 31 is angled just less than 90° which is well above the minimum 45° threshold value. Theexpansion region 30 also has a trailingwall 33. The trailingwall 33 may be angled with respect to the flow direction A. Generally, the angle at which the trailingwall 33 is not significant and may be any angle. For example, in one embodiment, the trailingwall 33 is angled a small amount which causes the trailingwall 33 to gradually taper back to the width of themicrofluidic channel 16. In yet another alternative, there is no trailingwall 33 and the expansion does not return to the original dimension of themicrofluidic channel 16. - In another embodiment as illustrated in
FIG. 1J , theexpansion region 30 includes a leadingwall 31 that is curved. In this regard, the leadingwall 31 initially starts a gradually divergence away from the upstreammicrofluidic channel 16 that increasingly diverges along the length of the leadingwall 31. In this embodiment, various tangents taken along different points of the leadingwall 31 will have significantly different angles compared to the axis of flow A. For example, near the start of the leadingwall 31, the angle θ1 is low and less than 45°. However, near the end of the leadingwall 31, the angle θ2 is steep and more than 45°. In the case of curved ordiscontinuous expansion regions 30 like what is illustrated inFIG. 1J , an average angle θAVE which represents the average angle with respect to the axis of flow A along the entire length of the leadingwall 31 should be greater than 45 (θAVE>45°). -
FIG. 1H illustrates a plan view ofseveral expansion regions 30 located along a length of amicrofluidic channel 16.FIG. 11 illustrates a cross-sectional view taken along the line A-A′ ofFIG. 1H . BothFIGS. 1H and 1I illustrate various dimensions of themicrofluidic channel 16 andexpansion regions 30. As stated previously, typical dimensions for the width (w) ofmicrofluidic channel 16 is in the range of 20 μm to 200 μm. Typical dimensions for the height (H) of themicrofluidic channel 16 are the range of 20 μm to 500 μm. Theexpansion region 30 may extend a distance (x) that is in the range between 80 μm and 800 μm but should be at least 80 μm. Theexpansion region 30 may extend a distance (y) that is in the range of 200 μm to 2 mm.Adjacent expansion regions 30 may be separated by distances (z) typically greater than 20 μm. In some embodiments, there may be asingle expansion region 30 such that there is noadjacent expansion region 30. The cross-sectional profile of themicrofluidic channel 16 may be substantially rectangular, trapezoidal, or square. The microfabrication process can lead to slightly trapezoidal cross-sections or corners that are slightly rounded. Thechannels 16 may also have circular or semi-circular cross sections although current fabrication techniques do not produce these geometries. These variations are intended to be covered by the methods and devices described herein. - Referring back to
FIG. 1A , theexpansion regions 30 may be disposed on opposing sides of themicrofluidic channel 16. This enables a singlemicrofluidic channel 16 to have greater capturing capabilities. Moreover, as explained in more detail below, this configuration enables a staggered arrangement ofexpansion regions 30 whenmultiple channels 16 are aligned in a parallel configuration. That is to say, adjacentmicrofluidic channels 16 can be closely packed together becauseexpansion regions 30 are offset from one another and interleave withexpansion regions 30 on adjacentmicrofluidic channels 16 as seen inFIG. 3 . Still referring toFIG. 1A , the larger-sized cells 12 are trapped within theexpansion regions 30 while the smaller-sized cells 12 are not trapped and continue to flow down themicrofluidic channel 16 where they exit viaoutlet 20. Larger-sized cells 12 (those illustrated in the expansion regions 30) are trapped within a vortex flow that is created within theexpansion regions 30. Smaller-sized cells 12, due to their size they are not trapped within the vortex flow and pass out of theexpansion regions 30. Thus, smaller-sized cells 12 are not trapped by the vortex in theexpansion regions 30 and continue to flow downstream in themicrofluidic channel 16. -
FIG. 2 illustrates amicrofluidic device 10 for isolatingcells 12 from a heterogeneoussolution containing cells 12 of different sizes as well as corresponding flows within themicrofluidic channel 16 andexpansion regions 30.FIG. 2 illustrates magnified views of three regions of themicrofluidic channel 16 andexpansion regions 30 as identified by views A, B, and C. As seen in view A, a heterogeneous population of differentsized cells 12 is pumped into the device via one of the syringe pumps 22, 24. The other syringe pump may contain a wash or other solution such as PBS. Initially, as seen in view A, thecells 12 are randomly dispersed is the y-direction. Thecells 12 experience two counteracting forces—a shear gradient lift force (FL shear gradient) that acts on thecells 12 to move the same toward the walls of themicrofluidic channel 16 and a wall effect lift force (FL wall effect) that repelscells 12 away from the walls of themicrofluidic channel 16. - By using a straight
microfluidic channel 16 with a rectangular cross-section, the dynamic equilibrium positions of the flowingcells 12 results in a dynamic lateral equilibrium position Xeq and uniform cell velocities as illustrated in view B ofFIG. 2 . Here, Xeq is defined as the distance between the center ofcells 12 and the wall of themicrofluidic channel 16. As thecells 12 progress to the expansion regions 30 (inFIG. 2 there are two (2) opposing expansion regions 30), thelarger cells 12 experiencing a larger FL shear gradient are pushed toward the vortex center and trapped, whereas thesmaller cells 12 are flushed out of theexpansion regions 30 and into the channel where they continue the downstream flow to theoutlet 20. Generally the FL shear gradient force scales with the cube of the cell diameter (a), causinglarger cells 12 to experience a larger FL shear gradient force. Size-dependent lateral migration drivescells 12 across streamlines past the detached boundary (separatrix) toward the vortex core where thecells 12 remain isolated and orbiting in the vortex. This enables size-selective trapping, as below a size cutoff, cells do not migrate at a sufficient rate to pass the separatrix and remain in focused streams, flowing out of theoutlet 20. -
FIG. 3 illustrates another embodiment of amicrofluidic device 10 for isolatingcells 12 that includes a plurality ofchannels 16 coupled to aninlet 18 and anoutlet 20.FIG. 3 illustrates eight (8)separate channels 16 that arranged generally parallel to one another. Eachmicrofluidic channel 16 has ten (10)separate expansion regions 30. Of course, it should be understood that any number ofchannels 16 may be used. The same applies with respect to the number ofseparate expansion regions 30 along a singlemicrofluidic channel 16. Spacing betweenadjacent expansion regions 30 along a singlemicrofluidic channel 16 may vary but 1 mm spacing has been found to work.Additional channels 16 may be added to create a massivelyparallel device 10. Thechannels 16 are straight withexpansion regions 30 onadjacent channels 16 being staggered with respect to one other. This design enablesadjacent channels 16 to be placed close to one another, thereby reducing the overall footprint of themicrofluidic device 10. WhileFIG. 3 illustrates an array ofchannels 16 in a two-dimensional layout it should be understood that the array ofchannels 16 could also be configured in a three-dimensional layout. The three-dimensional configuration would allow even more throughput. - In the device of
FIG. 3 , themicrofluidic channel 16 is a rectangular high-aspect ratio channel with a width of 50 μm and a height of 70 μm. Theinlet 18 includes afirst inlet 18′ for the sample containing thecells 12 and asecond inlet 18″ that contains PBS or other wash solution. Theduel inlet 18′, 18″ arrangement allows for easy and rapid solution exchange within themicrofluidic device 10, providing, for example, a means to flushun-trapped cells 12 and to enhance the final enrichment ratio and the purity of the collected samples. The length of themicrofluidic device 10 was several centimeters long. Theexpansion regions 30 were placed in an alternating pattern in order to place the maximum number ofexpansion regions 30 in a given compact footprint. In the device ofFIG. 3 , the expansion regions were squares having dimensions of 400 μm×400 μm. - Once the
cells 12 are trapped within theexpansion regions 30, thecells 12 may be released from theexpansion regions 30 by allowing the vortices to reduce in size and ultimately dissipate. This can be accomplished by lowering the input flow rate (e.g., reduce flow rate(s) ofpumps 22, 24). The reduced flow rate reduced the vortex size allowing thecells 12 trapped therein to be released into the flow of themicrofluidic channel 16 and carried out theoutlet 20 of the device. A flow rate of around 4 ml/minute has been found to work best with the device ofFIG. 3 . Alternatively, the flow rate may be rapidly decreased to substantially zero to stop the flow of fluid through themicrofluidic device 10. In this alternative, thecells 12 can be collected on-chip rather than off-chip. - The
microfluidic device 10 ofFIG. 3 was applied to separating and concentrating cancer cells (diameter of 20 micrometers) from normal human blood cells (diameters range from 2 to 15 micrometers) to demonstrate utility for size-based enrichment and concentration in a high-throughput manner. Enriching and concentrating cancer cells from blood is particularly important for clinical diagnostics as circulating tumor cells (CTCs) can provide real-time information on patient status and monitoring of cancer therapies. Isolating viable CTCs from blood in a quick, effective and label-free approach remains a significant technical challenge—CTCs are rare events at rates as low as one cell per one billion blood cells. While current strategies focus on enumeration of CTCs for diagnostics, there is a critical need for gathering larger sample sizes of viable CTCs for research purposes. This requires processing large blood volumes with higher throughputs and enriching target cells without the attachment to modified substrates or magnetic beads, providing an advantage for individually selecting captured cells for further analysis or culture. - This
device 10 addresses the need for rare cell enrichment with a massively parallel device that processes liquid volumes in the mL/min range, enriches target cells through size and density-based separation, and releases captured cells into a smaller concentrated volume. To demonstrate rare cell enrichment, fluorescently-labeled breast cancer cells (MCF-7) spiked into diluted human blood was injected into adevice 10 similar to that illustrated inFIG. 3 at 4.4 mL/min rate. MCF7 breast cancer cells were cultured in media containing DMEM supplemented with 10% FBS, 1% bovine insulin, and 1% penicillin/streptomycin were trypsinized and resuspended before use. Blood was collected from healthy human volunteers by a trained physician and diluted in PBS to 5-20% for experiments. - At these high flow rates channel deformation was observed in the upstream vortex reservoirs, however trapping is not significantly impacted given that downstream vortex chambers operating closer to ambient pressure remain un-deformed. Higher operational flow rates are instead limited by bond strength.
- Spiked MCF-7 cells included single cells and 2-4 cell clusters, as clustered cells have been shown to be present at significant levels in clinical samples. Blood and cancer cells were observed to enter and orbit in the vortices during the injection step as illustrated in the schematic view of a
single expansion region 30 in the upper panel ofFIG. 4A . The lower panel ofFIG. 4A illustrates a microscopic image showing a trapped cancer cell along with red blood cells contained in theexpansion region 30. Red blood cells were observed to enter vortices even though particles of similar size did not migrate into vortices in experiments with dilute samples. Likely, the high cell concentration induces collisions and hydrodynamic disturbances between cells that lead to cross-stream migration and entrance into vortices. - Additionally, there is a maximum capacity of cells each
expansion region 30 can maintain. After the vortex occupies the entire expansion region 30 a maximum of ˜40 single MCF7 cells can be maintained over a range of higher flow rates. For most spiking experiments conditions were kept well below this maximum. Once the solution was completely processed, the vortex-trapped cells were “washed” with PBS without disrupting the vortices. This is illustrated in the upper panel ofFIG. 4B . The lower panel ofFIG. 4B illustrates a microscopic image showing the still trapped cancer cell after a PBS wash solution has been introduced to remove the smaller and denser RBCs. Interestingly, it was observed that blood cells that initially entered the vortex were not stably trapped and quickly exited from the traps and out of the system leaving only the larger stably trapped cancer cells orbiting. Red and white blood cells have both higher density and/or smaller size, and therefore cannot form stable orbits. Washed cells were released into one well of a 96-well-plate for characterization and enumeration. - The
microfluidic device 10 performs well when quantifying key metrics for target cell concentration, enrichment, and purity. 10 mL volume blood samples (n≧6 samples) of 5% v/v blood (i.e., 0.5 mL whole blood or ˜2.5 billion blood cells) spiked with ˜500 cancer cells were concentrated to a final volume of less than 200 mL (20-fold volumetric concentration) with relatively little blood cell contamination in <3 min. This corresponds to an enrichment ratio (the ratio of target cancer cells to contaminant blood cells in the output divided by the same ratio in the input solution) of 3.4 million as seen inFIG. 5A . This high level of enrichment leads to high purity of the cancer cells in the 200 mL final volume: ˜40% as seen inFIG. 5B (an average of 102±21 cancer cells, and 221±155 blood cells). Blood samples without spiked cancer cells (n=3) that were processed with themicrofluidic device 10 and samples were collected in the well and were found to have 772±283 red blood cells and 4±1 CD45+ white blood cells, which is similar to the amount of blood cell contaminants found in the microwells using spiked blood samples. The level of enrichment achieved is comparable to molecular affinity-based and filter-based approaches for target cell separation which have reported enrichments from 1 million to 10 million. The purity of the processed sample is high when compared to affinity-based approaches which report purities of spiked cancer cells of 9.2 to 14.0%. Reducing the dilution of blood in processed samples leads to increases in cell-processing throughput, but also results in reduced capture efficiency of spiked cells. As seen inFIG. 5C , 10 to 20% of the spiked cancer cells were recovered, with decreasing capture efficiency with increasing blood concentrations. Higher blood concentrations lead to higher fluid viscosities which modify the fluid vortex size and position, resulting in lower trapping efficiency. - This relatively low capture efficiency at higher blood concentrations suggests that in order for this technique to be useful in isolating ultra-rare cells occurring at 1-10 cells/mL, a large volume of blood must be processed (10 mL or more). However, the high throughput of the
microfluidic device 10 described herein (˜5 mL/min of diluted blood for a 2 cm2 chip) indicates that operation on large volumes in a reasonable time period (<30 min) is achievable. - Cells captured in the
microfluidic device 10 maintained high levels of viability. No significant changes were observed in cell viability (90.1% vs. 90.3% initial) after injecting cells through the device as determined by a fluorescent live/dead assay. Viable cells may be important for some sample preparation applications. Cells captured and released from themicrofluidic device 10 are available for standard molecular assays such as immunostaining. To this end, unlabeled spiked blood samples were enriched with themicrofluidic device 10. Cancer cells were then released and labeled in a microwell. Cancer cells stained positive for Cytokeratin-PE and DAPI and negative for CD45. This ability to enrich on one device but transfer cells in a small volume for further processing offers significant advantages for rare single cell analysis. -
FIGS. 4C-4F illustrate the results of similar enrichment of a blood sample spiked with HeLa cells using themicrofluidic device 10 ofFIG. 3 at a Reynolds number (Rc) of 270. Themicrofluidic device 10 is flushed with PBS wash once the HeLa cells were captured in theexpansion regions 30. The trapped HeLa cells were released from theexpansion regions 30 by reducing the flow rate to Rc=5.FIG. 4G illustrates a comparison of the capturing efficiency of themicrofluidic device 10 as a function of cell concentration. The number of cells indicates the number of spiked HeLa cells processed through themicrofluidic device 10. - The
microfluidic device 10 was also used to effectively label cells for specific molecular markers. In traditional centrifugation, cell samples are labeled for specific markers through a series of labeling and washing steps. This includes incubating the cells with labeling reagents in a centrifuge tube, concentrating the cells into a pellet with a benchtop centrifuge, removing the supernatant layer containing unbound labeling reagents through manual aspiration, and manually resuspending the cells in a new medium. These operations were performed within themicrofluidic device 10 by trapping the cells within fluid vortices and sequentially exposing trapped orbiting cells to labeling reagents, followed by a PBS wash solution. Labeled cells were then released within a small volume into a collection vial by reducing flow. -
FIGS. 6A-6D illustrate, respectively, the trapping (FIG. 6A ), first solution exchange (FIG. 6B ), reaction (FIG. 6C ), and second solution exchange (FIG. 6D ).FIGS. 6E-6H illustrate, respectively, microscope images corresponding toFIGS. 6A-6D of actual MCF7 cells incubated with biotinylated EpCAM that were injected into themicrofluidic device 10. As seen inFIG. 6E , cells are trapped in the vortex, undergoing a constant rotating and orbiting motion.FIG. 6F illustrates the first solution exchange with streptavidin-coated microspheres. The streptavidin-coated microspheres enter theexpansion region 30.FIG. 6G illustrates the continuous reaction of the streptavidin-coated microspheres with the MCF7 cells.FIG. 6H illustrates a solution exchange with a second solution (i.e., PBS wash). The PBS wash removes unbound microspheres (arrow A). After the wash is complete the cells are released from vortex traps by lowering the flow rate through themicrofluidic device 10 wherein the cells are collected into a 96-well-plate for characterization. Arrows B inFIG. 6H point to particles that are increasingly bound to the cell over 2 minutes. - The ability to hold cells stably in place within fluid vortices allows for multiple solution exchanges with labeling agents and wash solutions in a format that can be automated. Each addition of a new solution takes approximately 100 ms for complete exchange. For the same labeling reaction a traditional centrifuge-based process requires six (6) centrifugation steps that includes three (3) washing steps and requires >30 minutes of sample preparation time (this excludes the incubation time with labeling reagents). Each centrifugation and wash step can potentially result in a loss of a small proportion of cells and requires between 5-10 min.
- Fast labeling is aided by cells that rotate and orbit in the fluid vortex such that they are exposed to a constantly refreshed milieu of molecular labels. In other words, strong convection of labeling reagents in the vortex leads to a very small depleted region of reagents near the cell surface and a strong gradient driving more reagents to the cell surface. This fast labeling was observed by examining the binding of streptavidin-coated microspheres to biotinylated anti-EpCAM antibodies on the cell surface (
FIGS. 6A-6H ). It was found that the cells in themicrofluidic device 10 accumulated the same number of microbeads in 5 minutes that cells prepared with the standard protocol accumulated in 30 minutes. Further, after 30 minutes, cells labeled with themicrofluidic device 10 on average had twice the number of microbeads bound per cell compared to standard methods. - Multiple sequential sample preparation steps enabled by a centrifuge (e.g., trapping fluorescent solution exchange, reaction, and wash) were successfully conducted using the
microfluidic device 10 illustrated inFIG. 7 . In this embodiment, themicrofluidic device 10 included threeinlets 18′, 18″, and 18″′. Oneinlet 18′ was coupled asyringe pump 22 that was used to deliver the cell sample. Thesecond syringe pump 24 was used to deliver the fluorescent agent. Thethird syringe pump 26 is used to deliver wash (PBS). Size-based trapping of cancer cells from blood, sequential fluorescent labeling, and analysis of released cells were conducted in <1 hour. Diluted human blood (10 mL) spiked with cancer cells was injected into themicrofluidic device 10 for ˜3 min to enrich the cancer cells. Trapped cells were sequentially prepared with a fixation agent (paraformaldehyde) and permeabilization agent and stained with fluorescent antibodies (anti-Cytokeratin-PE & DAPI) for 20 min. The sequence of trapping, first solution exchange, reaction, and second solution exchange is seen inFIGS. 8A-8D . Cells were then washed with PBS for <1 min, and collected into a 96-well-plate for characterization. Collected cells labeled positive for cytokeratin and DAPI, indicating the success of sequential sample preparation as illustrated inFIG. 9 which shows a fluorescent image of a cluster of cells that was sequentially trapped inside the fluid vortex, fixed with paraformaldehyde, permeabilized, and labeled with anti-Cytokeratin-PE & DAPI. As seen in FIG. 1A0, MCF7 cells covered with biotinylated anti-EpCAM are coated with streptavidin conjugated microbeads in <5 minutes at the same level as a standard off-chip protocol after 30 minutes. FIG. 1A1 illustrates uniform labeling with microbeads over the cell population after 30 minutes. Further, the microfluidic device 10 (centrifuge-on-chip) results in a larger number of beads bound per cell. The results above demonstrate a complete route to automation of all of the sample preparation processes required for cell analysis in a single simple platform. - The
devices 10 and methods described herein are useful for inexpensive and rapid circulating tumor cell (CTC) analysis. CTC detection and enumeration is a valuable and promising diagnostic tool for monitoring breast cancer status and outcome. CTCs are tumor-derived cells that spread via the bloodstream and can reflect the aggressiveness of a tumor. CTCs are rare events at rates as low as one cell per one billion cells. CTC isolation thus presents a significant technological challenge. Thedevices 10 and methods described herein can exploit the cell size difference between CTCs and blood cells (CTCs are 2-4 times larger than RBCs) to isolate viable CTCs from whole blood in a label-free manner. Other potential applications of thedevices 10 and methods include prenatal testing that involves the isolation of fetal cells from maternal blood cells. Fetal cells of interest can be isolated without labeling or external bulk machines. - While the
microfluidic device 10 has particular application for isolating CTCs, other applications include concentratingcells 12 obtained from a sample. For example,cells 12 of interest having a size that enables trapping withinexpansion regions 30 can be captured then released into a sample in concentrated form. For example,cells 12 contained in a biological source of fluid like urine, pleural fluid, and peritoneal washes can be run through themicrofluidic device 10 to concentratecells 12 contained therein. In this regard, themicrofluidic device 10 is well suited for concentratingcells 12. For example, on a volumetric basis, themicrofluidic device 10 can concentratecells 12 more than ten (10) or twenty (20) times the concentration of thecells 12 in the initial solution. - While embodiments have been shown and described, various modifications may be made without departing from the scope of the inventive concepts disclosed herein. For example, while several embodiments have been described herein it should be appreciated that various aspects or elements are interchangeable with other separately embodiments. The invention(s), therefore, should not be limited, except to the following claims, and their equivalents.
Claims (29)
1.-71. (canceled)
72. A method, comprising:
flowing a solution in a microfluidic channel at a first flow rate to capture one or more particles in a vortex generated in the microfluidic channel, the solution including the one or more particles, the microfluidic channel associated with an expansion region disposed along the length thereof, the expansion region including an abrupt increase in a cross-sectional dimension of the microfluidic channel followed by an abrupt decrease in the cross-sectional dimension of the microfluidic channel, the vortex being generated within the expansion region, the one or more particles having a diameter greater than or equal to 10 μm; and
changing the flow rate of solution from the first flow rate to a second flow rate to release the one or more particles from the expansion region, the second flow rate being less than the first flow rate.
73. The method of claim 72 , further comprising extracting the released one or more particles from an outlet of the microfluidic channel.
74. The method of claim 72 , the changing the flow rate including dissipating the vortex to permit the one or more particles to release from the expansion region into the microfluidic channel.
75. The method of claim 72 , wherein the second flow rate is substantially zero.
76. The method of claim 72 , wherein the expansion region is a first expansion region of a set of expansion regions of the microfluidic channel.
77. The method of claim 72 , the one or more particles including one or more cancer cells.
78. The method of claim 72 , wherein the solution comprises a bodily fluid.
79. A system, comprising:
a microfluidic channel, the microfluidic channel associated with an expansion region disposed along the length thereof, the expansion region including an abrupt increase in a cross-sectional dimension of the microfluidic channel followed by an abrupt decrease in the cross-sectional dimension of the microfluidic channel;
a pump fluidically coupled to the microfluidic channel, the pump configured to control a flow rate of a solution in the microfluidic channel; and
a processor operably coupled to the pump, the processor and the pump collectively configured to:
flow the solution in the microfluidic channel at a first flow rate to capture one or more particles in a vortex generated in the expansion region, the solution including the one or more particles, the one or more particles having a diameter greater than or equal to 10 μm; and
release the one or more particles from the expansion region by changing the flow rate of solution from the first flow rate to a second flow rate, the second flow rate being less than the first flow rate.
80. The system of claim 79 , wherein the pump comprises a pressurized source of gas configured to pump the solution in the microfluidic channel at controlled pressures to generate the first flow rate and the second flow rate.
81. The system of claim 79 , wherein the expansion region is a first expansion region of a set of expansion regions, the microfluidic channel associated with the set of expansion regions.
82. The system of claim 79 , further comprising a microfluidic substrate, wherein the microfluidic channel is a first microfluidic channel of a set of microfluidic channels, the microfluidic substrate including the set of microfluidic channels.
83. The system of claim 79 , the processor and the pump collectively further configured to extract the released one or more particles from an outlet of the microfluidic channel.
84. The system of claim 79 , the processor and the pump collectively further configured to change the flow rate by dissipating the vortex to permit the one or more particles to release from the expansion region into the microfluidic channel.
85. The system of claim 79 , a cross-section of the expansion region selected from the group consisting of: a rectangle, a square, a triangle, a polygonal, and a semi-circle.
86. The system of claim 79 , the expansion region including a leading wall extending at least 45° with respect to an axis of flow of the microfluidic channel.
87. A method, comprising:
flowing a solution in a microfluidic channel at a flow rate to capture one or more particles in a vortex generated in the microfluidic channel, the solution including the one or more particles, the microfluidic channel associated with an expansion region disposed along the length thereof, the expansion region including an abrupt increase in a cross-sectional dimension of the microfluidic channel followed by an abrupt decrease in the cross-sectional dimension of the microfluidic channel, the vortex being generated within the expansion region, the one or more particles having a diameter greater than or equal to 10 μm; and
dissipating the vortex to release, into the microfluidic channel, the one or more particles from the expansion region.
88. The method of claim 87 , wherein the solution is a first solution including the one or more particles and the flow rate is a first flow rate, the dissipating including flowing a second solution in the microfluidic channel at a second flow rate, the second flow rate being less than the first flow rate.
89. The method of claim 87 , further comprising extracting the released one or more particles from an outlet of the microfluidic channel.
90. The method of claim 87 , wherein the expansion region is a first expansion region of a set of expansion regions of the microfluidic channel.
91. The method of claim 87 , the one or more particles including one or more cancer cells.
92. The method of claim 87 , wherein the solution comprises a bodily fluid.
93. A system, comprising:
a microfluidic channel, the microfluidic channel associated with an expansion region disposed along the length thereof, the expansion region including an abrupt increase in a cross-sectional dimension of the microfluidic channel followed by an abrupt decrease in the cross-sectional dimension of the microfluidic channel;
a pump fluidically coupled to the microfluidic channel, the pump configured to control a flow rate of a solution in the microfluidic channel; and
a processor operably coupled to the pump, the processor and the pump collectively configured to:
flow the solution in the microfluidic channel at a first flow rate to capture one or more particles in a vortex generated in the expansion region, the solution including the one or more particles, the one or more particles having a diameter greater than or equal to 10 μm; and
dissipate the vortex to release, into the microfluidic channel, the one or more particles from the expansion region.
94. The system of claim 93 , wherein the expansion region is a first expansion region of a set of expansion regions, the microfluidic channel associated with the set of expansion regions.
95. The system of claim 93 , further including a microfluidic substrate, wherein the microfluidic channel is a first microfluidic channel of a set of microfluidic channels, the microfluidic substrate including the set of microfluidic channels.
96. The system of claim 93 , the processor and the pump collectively further configured to extract the released one or more particles from an outlet of the microfluidic channel.
97. The system of claim 93 , the microfluidic channel further including a first inlet and a second inlet, wherein the solution is a first solution including the one or more particles and the flow rate is a first flow rate, the processor and the pump collectively further configured to:
flow the first solution in the microfluidic channel via the first inlet at a first flow rate to capture the one or more particles in the vortex; and
dissipate the vortex by flowing a second solution in the microfluidic channel via the second inlet at a second flow rate, the second flow rate being less than the first flow rate.
98. The system of claim 93 , the expansion region including a leading wall extending at least 45° with respect to an axis of flow of the microfluidic channel.
99. The system of claim 93 , wherein the second solution comprises a staining solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/345,359 US20170114385A1 (en) | 2010-09-14 | 2016-11-07 | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38284010P | 2010-09-14 | 2010-09-14 | |
PCT/US2011/051224 WO2012037030A2 (en) | 2010-09-14 | 2011-09-12 | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
US201313823112A | 2013-03-14 | 2013-03-14 | |
US14/819,302 US10407709B2 (en) | 2010-09-14 | 2015-08-05 | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
US14/948,119 US10351894B2 (en) | 2010-09-14 | 2015-11-20 | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
US15/345,359 US20170114385A1 (en) | 2010-09-14 | 2016-11-07 | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/948,119 Continuation US10351894B2 (en) | 2010-09-14 | 2015-11-20 | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170114385A1 true US20170114385A1 (en) | 2017-04-27 |
Family
ID=45832184
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/823,112 Active 2031-10-24 US9133499B2 (en) | 2010-09-14 | 2011-09-12 | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
US14/819,302 Active 2033-07-23 US10407709B2 (en) | 2010-09-14 | 2015-08-05 | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
US14/948,119 Active 2031-12-20 US10351894B2 (en) | 2010-09-14 | 2015-11-20 | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
US15/345,359 Abandoned US20170114385A1 (en) | 2010-09-14 | 2016-11-07 | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/823,112 Active 2031-10-24 US9133499B2 (en) | 2010-09-14 | 2011-09-12 | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
US14/819,302 Active 2033-07-23 US10407709B2 (en) | 2010-09-14 | 2015-08-05 | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
US14/948,119 Active 2031-12-20 US10351894B2 (en) | 2010-09-14 | 2015-11-20 | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
Country Status (7)
Country | Link |
---|---|
US (4) | US9133499B2 (en) |
EP (1) | EP2616551B1 (en) |
JP (1) | JP5920895B2 (en) |
CN (2) | CN104741157B (en) |
AU (2) | AU2011302302B2 (en) |
CA (1) | CA2809877C (en) |
WO (1) | WO2012037030A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10351894B2 (en) | 2010-09-14 | 2019-07-16 | The Regents Of The University Of California | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
US10357771B2 (en) | 2017-08-22 | 2019-07-23 | 10X Genomics, Inc. | Method of producing emulsions |
US10544413B2 (en) | 2017-05-18 | 2020-01-28 | 10X Genomics, Inc. | Methods and systems for sorting droplets and beads |
WO2020150781A1 (en) * | 2019-01-23 | 2020-07-30 | Haplomic Technologies Pty Ltd | Microfluidic device |
US11660601B2 (en) | 2017-05-18 | 2023-05-30 | 10X Genomics, Inc. | Methods for sorting particles |
US11833515B2 (en) | 2017-10-26 | 2023-12-05 | 10X Genomics, Inc. | Microfluidic channel networks for partitioning |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2831223C (en) | 2011-03-24 | 2019-04-02 | Anpac Bio-Medical Science (Lishui) Co., Ltd. | Micro-devices for disease detection |
JP2014512839A (en) * | 2011-05-05 | 2014-05-29 | アンパック バイオ−メディカル サイエンス カンパニー リミテッド | Device for detecting tumor cells |
US9541480B2 (en) | 2011-06-29 | 2017-01-10 | Academia Sinica | Capture, purification, and release of biological substances using a surface coating |
US10466160B2 (en) | 2011-08-01 | 2019-11-05 | Celsee Diagnostics, Inc. | System and method for retrieving and analyzing particles |
WO2013019491A1 (en) | 2011-08-01 | 2013-02-07 | Denovo Sciences | Cell capture system and method of use |
US9404864B2 (en) | 2013-03-13 | 2016-08-02 | Denovo Sciences, Inc. | System for imaging captured cells |
US10564147B2 (en) | 2012-05-25 | 2020-02-18 | The Regents Of The University Of California | Microfluidic systems for particle trapping and separation using cavity acoustic transducers |
WO2014061631A1 (en) * | 2012-10-15 | 2014-04-24 | 国立大学法人名古屋大学 | Microchannel chip for microparticle separation, microparticle separation method and system for microparticle separation using chip |
US9857333B2 (en) | 2012-10-31 | 2018-01-02 | Berkeley Lights, Inc. | Pens for biological micro-objects |
WO2014078779A1 (en) * | 2012-11-16 | 2014-05-22 | Lightstat, Llc | Disposable sample collection method and apparatus |
US9752181B2 (en) | 2013-01-26 | 2017-09-05 | Denovo Sciences, Inc. | System and method for capturing and analyzing cells |
MX2015011605A (en) * | 2013-03-15 | 2016-05-09 | Adama Makhteshim Ltd | Termiticide composition and methods for treating termites. |
US9856535B2 (en) | 2013-05-31 | 2018-01-02 | Denovo Sciences, Inc. | System for isolating cells |
US10391490B2 (en) | 2013-05-31 | 2019-08-27 | Celsee Diagnostics, Inc. | System and method for isolating and analyzing cells |
CN105431726A (en) * | 2013-06-25 | 2016-03-23 | 华盛顿大学商业中心 | Self-digitization of sample volumes |
EP3027730A4 (en) * | 2013-07-29 | 2016-08-31 | 9493662 Canada Inc | Microfluidic cell culture systems |
US9029109B2 (en) * | 2013-08-07 | 2015-05-12 | President And Fellows Of Harvard College | Microfluidic vortex-assisted electroporation system and method |
CN105683750B (en) * | 2013-10-16 | 2020-02-28 | 明测生物医疗有限公司 | Microfluidic sorter for cell detection and separation |
EP3783094B1 (en) | 2013-10-22 | 2023-10-11 | Berkeley Lights, Inc. | Micro-fluidic devices for assaying biological activity |
CN110437975B (en) * | 2013-10-22 | 2023-06-09 | 伯克利之光生命科技公司 | Microfluidic device with isolated pens and method of testing biological micro-objects using same |
KR102221894B1 (en) * | 2013-10-22 | 2021-03-03 | 버클리 라잇츠, 인크. | Microfluidic devices having isolation pens and methods of testing biological micro-objects with same |
KR102346066B1 (en) * | 2013-10-22 | 2021-12-31 | 버클리 라잇츠, 인크. | Exporting a selected group of micro-objects from a micro-fluidic device |
US9889445B2 (en) | 2013-10-22 | 2018-02-13 | Berkeley Lights, Inc. | Micro-fluidic devices for assaying biological activity |
DK3060912T3 (en) * | 2013-10-22 | 2020-09-28 | Berkeley Lights Inc | PROCEDURE AND MICROFLUID DEVICE FOR ANALYSIS OF BIOLOGICAL ACTIVITY |
SG2013090790A (en) * | 2013-12-04 | 2015-07-30 | Clearbridge Mfluidics Pte Ltd | A microfluidic device |
WO2015156876A2 (en) * | 2014-01-17 | 2015-10-15 | Massachusetts Institute Of Technology | Integrated electrical profiling system for measuring leukocytes activation from whole blood |
EP3126814B1 (en) | 2014-04-01 | 2019-06-12 | Academia Sinica | Methods and systems for cancer diagnosis and prognosis |
US20150306599A1 (en) | 2014-04-25 | 2015-10-29 | Berkeley Lights, Inc. | Providing DEP Manipulation Devices And Controllable Electrowetting Devices In The Same Microfluidic Apparatus |
US11192107B2 (en) | 2014-04-25 | 2021-12-07 | Berkeley Lights, Inc. | DEP force control and electrowetting control in different sections of the same microfluidic apparatus |
WO2015200857A1 (en) * | 2014-06-27 | 2015-12-30 | The Regents Of The University Of California | Apparatus and method for label-free analysis of rare cells from bodily fluids |
WO2016011059A1 (en) * | 2014-07-14 | 2016-01-21 | President And Fellows Of Harvard College | Drug cocktail analyses using microscale vortex-assisted electroporation |
US10112198B2 (en) | 2014-08-26 | 2018-10-30 | Academia Sinica | Collector architecture layout design |
FI127992B (en) * | 2014-08-29 | 2019-07-15 | Svanbaeck Sami | Method and system for determining dissolution properties of matter |
WO2016094333A1 (en) | 2014-12-08 | 2016-06-16 | Berkeley Lights, Inc. | Actuated microfluidic structures for directed flow in a microfluidic device and methods of use thereof |
US9996920B2 (en) | 2014-12-09 | 2018-06-12 | Berkeley Lights, Inc. | Automated detection and repositioning of micro-objects in microfluidic devices |
CN107206377B (en) | 2014-12-09 | 2020-02-11 | 伯克利之光生命科技公司 | Automated detection of positive assay regions in microfluidic devices |
WO2016094715A2 (en) | 2014-12-10 | 2016-06-16 | Berkeley Lights, Inc. | Movement and selection of micro-objects in a microfluidic apparatus |
WO2016168492A1 (en) | 2015-04-14 | 2016-10-20 | Hur Soojung Claire | Electrode array for vortex-assisted electroporation |
US10101250B2 (en) | 2015-04-22 | 2018-10-16 | Berkeley Lights, Inc. | Manipulation of cell nuclei in a micro-fluidic device |
US10751715B1 (en) | 2015-04-22 | 2020-08-25 | Berkeley Lights, Inc. | Microfluidic reporter cell assay methods and kits thereof |
SG10202100281RA (en) | 2015-04-22 | 2021-02-25 | Berkeley Lights Inc | Microfluidic cell culture |
SG11201708557TA (en) | 2015-04-22 | 2017-11-29 | Berkeley Lights Inc | Freezing and archiving cells on a microfluidic device |
US20180161774A1 (en) * | 2015-06-17 | 2018-06-14 | The Regents Of The University Of California | High efficiency microfluidic device for trapping circulating tumor cells |
KR101684138B1 (en) * | 2015-06-30 | 2016-12-21 | 한국표준과학연구원 | Apparatus and method for small degree off-axis micro-channel system to improve performance of solution immersed silicon biosensors |
US9862941B2 (en) | 2015-10-14 | 2018-01-09 | Pioneer Hi-Bred International, Inc. | Single cell microfluidic device |
US10799865B2 (en) | 2015-10-27 | 2020-10-13 | Berkeley Lights, Inc. | Microfluidic apparatus having an optimized electrowetting surface and related systems and methods |
US11666913B2 (en) | 2015-11-23 | 2023-06-06 | Berkeley Lights, Inc | In situ-generated microfluidic isolation structures, kits and methods of use thereof |
WO2017100347A1 (en) | 2015-12-08 | 2017-06-15 | Berkeley Lights, Inc. | Microfluidic devices and kits and methods for use thereof |
SG11201805473SA (en) | 2015-12-30 | 2018-07-30 | Berkeley Lights Inc | Microfluidic devices for optically-driven convection and displacement, kits and methods thereof |
TWI808934B (en) | 2015-12-31 | 2023-07-21 | 美商伯克利之光生命科技公司 | Tumor infilitrating cells engineered to express a pro-inflammatory polypeptide |
WO2017123978A1 (en) | 2016-01-15 | 2017-07-20 | Berkeley Lights, Inc. | Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor |
US10107726B2 (en) | 2016-03-16 | 2018-10-23 | Cellmax, Ltd. | Collection of suspended cells using a transferable membrane |
EP3429753A4 (en) | 2016-03-16 | 2019-11-06 | Berkeley Lights, Inc. | Methods, systems and devices for selection and generation of genome edited clones |
US10675625B2 (en) | 2016-04-15 | 2020-06-09 | Berkeley Lights, Inc | Light sequencing and patterns for dielectrophoretic transport |
WO2017181186A1 (en) * | 2016-04-15 | 2017-10-19 | Vortex Biosciences, Inc. | Microfluidic chips and cartridges and systems utilizing microfluidic chips and cartridges |
IL262367B (en) | 2016-04-15 | 2022-09-01 | Berkeley Lights Inc | Methods, systems and kits for sequestration pen-based assays |
KR20190010641A (en) | 2016-05-26 | 2019-01-30 | 버클리 라잇츠, 인크. | Covalently modified surfaces, kits, and methods of preparation and use |
CN115993462A (en) * | 2016-06-08 | 2023-04-21 | 加利福尼亚大学董事会 | Method and device for treating tissues and cells |
KR102456488B1 (en) | 2016-07-21 | 2022-10-19 | 버클리 라잇츠, 인크. | Classification of T lymphocytes in microfluidic devices |
EP3500662B1 (en) * | 2016-08-20 | 2022-10-05 | The Regents Of The University Of California | High-throughput system and method for the temporary permeabilization of cells |
US10717086B2 (en) * | 2016-08-29 | 2020-07-21 | The Regents Of The University Of California | Integrated system for isolation and emulsification of particles and cells |
EP3525933A1 (en) | 2016-10-11 | 2019-08-21 | The Regents of the University of California | Systems and methods to encapsulate and preserve organic matter for analysis |
CN107955788A (en) * | 2016-10-14 | 2018-04-24 | 中国科学院大连化学物理研究所 | A kind of micro fluid dynamcis method on organ chip |
WO2018119296A1 (en) * | 2016-12-22 | 2018-06-28 | The Charles Stark Draper Laboratory, Inc. | System and method of using a microfluidic electroporation device for cell treatment |
AU2017388874A1 (en) | 2016-12-30 | 2019-07-18 | Berkeley Lights, Inc. | Methods for selection and generation of genome edited T cells |
US11213823B2 (en) * | 2017-01-11 | 2022-01-04 | The Regents Of The University Of California | Microfluidic in situ labelling on stable interfaces |
CN106823475B (en) * | 2017-02-07 | 2023-01-24 | 重庆科技学院 | Blood shunt |
US11213824B2 (en) | 2017-03-29 | 2022-01-04 | The Research Foundation For The State University Of New York | Microfluidic device and methods |
WO2018227210A1 (en) * | 2017-06-09 | 2018-12-13 | The Regents Of The University Of California | High-efficiency encapsulation in droplets based on hydrodynamic vortices control |
US11517901B2 (en) | 2017-06-09 | 2022-12-06 | The Regents Of The University Of California | High-efficiency particle encapsulation in droplets with particle spacing and downstream droplet sorting |
WO2019016600A2 (en) * | 2017-07-18 | 2019-01-24 | Avectas Limited | Payload delivery across cell membranes using continuous flow fluidic system |
EP3651903A4 (en) | 2017-08-29 | 2021-06-16 | Bio-Rad Laboratories, Inc. | System and method for isolating and analyzing cells |
EP3655158A1 (en) * | 2017-09-07 | 2020-05-27 | Sony Corporation | Particle capturing chamber, particle capturing chip, particle capturing method, apparatus, and particle analysis system |
WO2019067319A2 (en) * | 2017-09-29 | 2019-04-04 | Schlumberger Technology Corporation | Microfluidic technique for detection of multi-contact miscibility |
WO2019075409A1 (en) | 2017-10-12 | 2019-04-18 | The Regents Of The University Of California | Microfluidic label-free isolation and identification of cells using fluorescence lifetime imaging (flim) |
EP3721209B1 (en) | 2017-10-15 | 2024-02-07 | Berkeley Lights, Inc. | Methods for in-pen assays |
WO2019079787A1 (en) | 2017-10-20 | 2019-04-25 | The Regents Of The University Of California | Microfluidic systems and methods for lipoplex-mediated cell transfection |
US11499127B2 (en) | 2017-10-20 | 2022-11-15 | The Regents Of The University Of California | Multi-layered microfluidic systems for in vitro large-scale perfused capillary networks |
JP2019086340A (en) * | 2017-11-02 | 2019-06-06 | シスメックス株式会社 | Cell detection method and cell detection system |
CN107974392A (en) * | 2017-12-27 | 2018-05-01 | 深圳市合川医疗科技有限公司 | A kind of method of circulating tumor cell in micro-fluidic chip and separating trap blood |
CN108359577B (en) * | 2018-01-29 | 2022-03-04 | 燕山大学 | Zebra fish egg rotation micro-operation system based on micro-fluid drive and control method |
KR102019602B1 (en) * | 2018-06-01 | 2019-09-06 | 주종일 | Microfluidic Chip for 3-Dimensional Cell Culture and Method of 3-Dimensional Cell Culture Using the Same |
US20210163866A1 (en) * | 2018-08-21 | 2021-06-03 | Hewlett-Packard Development Company, L.P. | Cell measurements after isolation from solutions in a microfluidic channel |
CN108854892B (en) * | 2018-08-23 | 2020-08-25 | 浙江工业大学上虞研究院有限公司 | Micro-reactor |
CN109666584A (en) * | 2018-12-29 | 2019-04-23 | 北京工业大学 | A kind of experimental provision can be used for carrying out circulating tumor cell sorting experiment |
IT201900002777A1 (en) * | 2019-02-26 | 2020-08-26 | Menarini Silicon Biosystems Spa | METHOD AND MICROFLUIDIC SYSTEM FOR THE ISOLATION OF PARTICLES |
US20220177819A1 (en) * | 2019-03-12 | 2022-06-09 | MxT Biotech | Microfluidic system for intracellular delivery of materials and method therefor |
US10633693B1 (en) | 2019-04-16 | 2020-04-28 | Celsee Diagnostics, Inc. | System and method for leakage control in a particle capture system |
CN109975265B (en) * | 2019-04-22 | 2020-06-16 | 中国矿业大学 | Three-dimensional contraction and expansion microfluidic device and method for multidirectional induced Dean flow |
EP3962652A4 (en) | 2019-04-30 | 2023-01-18 | Berkeley Lights, Inc. | Methods for encapsulating and assaying cells |
US11273439B2 (en) | 2019-05-07 | 2022-03-15 | Bio-Rad Laboratories, Inc. | System and method for target material retrieval from microwells |
KR20220016477A (en) | 2019-05-07 | 2022-02-09 | 바이오 래드 래버러토리스 인코오포레이티드 | Systems and Methods for Automated Single Cell Processing |
CN111909823B (en) * | 2019-05-08 | 2023-04-18 | 清华大学 | Inertial micro-fluidic chip for enriching circulating tumor cells |
SG11202112898WA (en) | 2019-06-14 | 2021-12-30 | Bio Rad Laboratories | System and method for automated single cell processing and analyses |
CN110257223A (en) * | 2019-07-15 | 2019-09-20 | 北京工业大学 | A kind of cell micro-environment regulation chip apparatus based on groove droplet capture |
CN114867556B (en) * | 2019-11-06 | 2023-09-15 | 高丽大学校算学协力团 | Droplet-based deformation method for delivering material into cells and chip therefor |
CN111060364A (en) * | 2019-11-20 | 2020-04-24 | 天津大学 | Integrated method for staining and screening tumor cells and matched microfluidic chip |
CN111040928B (en) * | 2019-12-27 | 2023-12-26 | 天津大学 | High-flux micro-fluidic chip for Crypthecodinium cohnii treatment and collection |
US20230033651A1 (en) * | 2020-01-08 | 2023-02-02 | The General Hospital Corporation | Microfluidic systems and methods for low-shear isolation of rare cells from large sample volumes |
CN111088146A (en) * | 2020-01-09 | 2020-05-01 | 天津大学 | Micro-fluidic chip for screening tumor cells from pleural effusion |
CN111207988B (en) * | 2020-02-18 | 2021-08-27 | 中南大学 | Ore pulp monitoring devices based on microfluid |
US11504719B2 (en) | 2020-03-12 | 2022-11-22 | Bio-Rad Laboratories, Inc. | System and method for receiving and delivering a fluid for sample processing |
CN111690534B (en) * | 2020-06-16 | 2023-05-30 | 东南大学 | Tumor cell multistage sorting device based on viscoelastic focusing technology |
WO2022067174A1 (en) * | 2020-09-28 | 2022-03-31 | Georgia Tech Research Corporation | Microfluidic devices for particle capture and methods thereof |
US11959186B2 (en) * | 2020-11-26 | 2024-04-16 | Changxin Memory Technologies, Inc. | Electroplating method and electroplating apparatus |
EP4019131A1 (en) | 2020-12-22 | 2022-06-29 | Albert-Ludwigs-Universität Freiburg | Microfluidic device and method for isolating objects |
USD1016323S1 (en) | 2021-04-09 | 2024-02-27 | Ananda Devices Inc. | Microfluidic slab |
USD1004127S1 (en) | 2021-04-09 | 2023-11-07 | Ananda Devices Inc. | Microfluidic slab |
CN113528447A (en) * | 2021-06-10 | 2021-10-22 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | Micro-fluidic chip and application thereof in sorting, amplifying and recycling tumor stem cells |
CN114395463B (en) * | 2021-12-10 | 2023-11-17 | 广州大学 | CTC enrichment and release system based on micro-fluidic and micro-optical tweezers arrays and preparation method |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6252375B1 (en) * | 2000-07-24 | 2001-06-26 | In-System Design, Inc. | Power management system and current augmentation and battery charger method and apparatus for a computer peripheral |
GB2375399A (en) | 2001-05-11 | 2002-11-13 | Suisse Electronique Microtech | Microfluidic system for the manipulation and concentration of particles suspended in fluid |
CA2518667C (en) | 2003-03-14 | 2011-07-19 | The Trustees Of Columbia University In The City Of New York | Systems and methods of blood-based therapies having a microfluidic membraneless exchange device |
US7767435B2 (en) | 2003-08-25 | 2010-08-03 | University Of Washington | Method and device for biochemical detection and analysis of subcellular compartments from a single cell |
JP2007522913A (en) * | 2003-10-03 | 2007-08-16 | フリーイェ・ユニヴェルシテイト・ブリュッセル | Method and apparatus for size separation of particles present in a fluid |
US7803599B2 (en) | 2004-01-16 | 2010-09-28 | University Of Washington | Steady streaming particle traps |
US20060079003A1 (en) * | 2004-10-12 | 2006-04-13 | Witty Thomas R | Apparatus and method for a precision flow assay |
US7682817B2 (en) * | 2004-12-23 | 2010-03-23 | Kimberly-Clark Worldwide, Inc. | Microfluidic assay devices |
CN101137440A (en) * | 2005-01-12 | 2008-03-05 | 因弗因斯医药瑞士股份有限公司 | A method of producing a microfluidic device and microfluidic devices |
US7993821B2 (en) | 2005-08-11 | 2011-08-09 | University Of Washington | Methods and apparatus for the isolation and enrichment of circulating tumor cells |
US8186913B2 (en) | 2007-04-16 | 2012-05-29 | The General Hospital Corporation | Systems and methods for particle focusing in microchannels |
US8841135B2 (en) | 2007-06-20 | 2014-09-23 | University Of Washington | Biochip for high-throughput screening of circulating tumor cells |
TW200920841A (en) * | 2007-09-25 | 2009-05-16 | Cytyc Corp | Microfluidic apparatus for manipulating imaging and analyzing cells of a cytological specimen |
CN101177663A (en) * | 2007-11-05 | 2008-05-14 | 吉林大学 | DNA separating micro-fluidic chip |
FR2931079B1 (en) | 2008-05-13 | 2010-07-30 | Commissariat Energie Atomique | DEVICE AND METHOD FOR SEPARATING A SUSPENSION |
FR2931141B1 (en) | 2008-05-13 | 2011-07-01 | Commissariat Energie Atomique | MICROFLUIDIC SYSTEM AND METHOD FOR THE SORTING OF AMAS FROM CELLS AND PREFERENCE FOR CONTINUOUS ENCAPSULATION THROUGH THEIR SORTING |
FR2931085B1 (en) * | 2008-05-13 | 2011-05-27 | Commissariat Energie Atomique | METHOD OF SORTING PARTICLES OR AMAS FROM PARTICLES IN A FLUID CIRCULATING IN A CHANNEL |
EP2335075A4 (en) | 2008-09-05 | 2011-12-14 | Scripps Research Inst | Methods for the detection of circulating tumor cells |
JP2012504243A (en) | 2008-09-26 | 2012-02-16 | ザ ジェネラル ホスピタル コーポレイション | Particle capture |
US20110070581A1 (en) | 2009-04-27 | 2011-03-24 | Amit Gupta | Separation of Leukocytes |
JP2010281701A (en) * | 2009-06-05 | 2010-12-16 | Tohoku Univ | Fine particle continuous sorting/measuring device and micro-fluid chip |
US8208138B2 (en) | 2009-09-24 | 2012-06-26 | University Of Cincinnati | Spiral microchannel particle separators, straight microchannel particle separators, and continuous particle separator and detector systems |
SG189778A1 (en) | 2009-10-20 | 2013-05-31 | Agency Science Tech & Res | Microfluidic system for trapping and detection of a biological entity in a sample |
AU2011302302B2 (en) | 2010-09-14 | 2014-12-11 | The Regents Of The University Of California | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
-
2011
- 2011-09-12 AU AU2011302302A patent/AU2011302302B2/en active Active
- 2011-09-12 CN CN201510088710.9A patent/CN104741157B/en active Active
- 2011-09-12 EP EP11825738.5A patent/EP2616551B1/en active Active
- 2011-09-12 JP JP2013528369A patent/JP5920895B2/en active Active
- 2011-09-12 US US13/823,112 patent/US9133499B2/en active Active
- 2011-09-12 CN CN201180044092.8A patent/CN103261436B/en active Active
- 2011-09-12 CA CA2809877A patent/CA2809877C/en active Active
- 2011-09-12 WO PCT/US2011/051224 patent/WO2012037030A2/en active Application Filing
-
2015
- 2015-02-23 AU AU2015200910A patent/AU2015200910B2/en active Active
- 2015-08-05 US US14/819,302 patent/US10407709B2/en active Active
- 2015-11-20 US US14/948,119 patent/US10351894B2/en active Active
-
2016
- 2016-11-07 US US15/345,359 patent/US20170114385A1/en not_active Abandoned
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10351894B2 (en) | 2010-09-14 | 2019-07-16 | The Regents Of The University Of California | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
US10407709B2 (en) | 2010-09-14 | 2019-09-10 | The Regents Of The University Of California | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
US11660601B2 (en) | 2017-05-18 | 2023-05-30 | 10X Genomics, Inc. | Methods for sorting particles |
US10544413B2 (en) | 2017-05-18 | 2020-01-28 | 10X Genomics, Inc. | Methods and systems for sorting droplets and beads |
US10610865B2 (en) | 2017-08-22 | 2020-04-07 | 10X Genomics, Inc. | Droplet forming devices and system with differential surface properties |
US10583440B2 (en) | 2017-08-22 | 2020-03-10 | 10X Genomics, Inc. | Method of producing emulsions |
US10549279B2 (en) | 2017-08-22 | 2020-02-04 | 10X Genomics, Inc. | Devices having a plurality of droplet formation regions |
US10766032B2 (en) | 2017-08-22 | 2020-09-08 | 10X Genomics, Inc. | Devices having a plurality of droplet formation regions |
US10821442B2 (en) | 2017-08-22 | 2020-11-03 | 10X Genomics, Inc. | Devices, systems, and kits for forming droplets |
US10898900B2 (en) | 2017-08-22 | 2021-01-26 | 10X Genomics, Inc. | Method of producing emulsions |
US11565263B2 (en) | 2017-08-22 | 2023-01-31 | 10X Genomics, Inc. | Droplet forming devices and system with differential surface properties |
US10357771B2 (en) | 2017-08-22 | 2019-07-23 | 10X Genomics, Inc. | Method of producing emulsions |
US11833515B2 (en) | 2017-10-26 | 2023-12-05 | 10X Genomics, Inc. | Microfluidic channel networks for partitioning |
WO2020150781A1 (en) * | 2019-01-23 | 2020-07-30 | Haplomic Technologies Pty Ltd | Microfluidic device |
Also Published As
Publication number | Publication date |
---|---|
CN103261436A (en) | 2013-08-21 |
WO2012037030A3 (en) | 2012-06-07 |
JP2013541331A (en) | 2013-11-14 |
CN103261436B (en) | 2015-03-25 |
US20160139015A1 (en) | 2016-05-19 |
WO2012037030A2 (en) | 2012-03-22 |
AU2011302302B2 (en) | 2014-12-11 |
JP5920895B2 (en) | 2016-05-25 |
EP2616551B1 (en) | 2020-08-19 |
EP2616551A4 (en) | 2016-05-04 |
US20150355060A1 (en) | 2015-12-10 |
AU2015200910B2 (en) | 2016-09-22 |
CA2809877A1 (en) | 2012-03-22 |
AU2015200910A1 (en) | 2015-03-12 |
US10351894B2 (en) | 2019-07-16 |
CN104741157B (en) | 2017-04-12 |
US9133499B2 (en) | 2015-09-15 |
US10407709B2 (en) | 2019-09-10 |
EP2616551A2 (en) | 2013-07-24 |
AU2011302302A1 (en) | 2013-03-21 |
US20130171628A1 (en) | 2013-07-04 |
CA2809877C (en) | 2021-11-23 |
CN104741157A (en) | 2015-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10351894B2 (en) | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices | |
US11944971B2 (en) | Sorting particles in a microfluidic device | |
Mach et al. | Automated cellular sample preparation using a Centrifuge-on-a-Chip | |
EP2731723B1 (en) | Methods for magnetic separation | |
CN107828651B (en) | Micro-fluidic chip for preparing single-cell micro-droplet sample | |
US20070059718A1 (en) | Systems and methods for enrichment of analytes | |
US20070059680A1 (en) | System for cell enrichment | |
US20070059781A1 (en) | System for size based separation and analysis | |
US20070059719A1 (en) | Business methods for prenatal Diagnosis | |
US20070059683A1 (en) | Veterinary diagnostic system | |
Huang et al. | A tunable micro filter modulated by pneumatic pressure for cell separation | |
Garg et al. | Whole-blood sorting, enrichment and in situ immunolabeling of cellular subsets using | |
Chen | On-chip preparation of biological cells using microfluidic arrays | |
Miwa et al. | Development of micro immunoreaction-based cell sorter for regenerative medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |